<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease - Rojas‐Reyes, MX - 2016 | Cochrane Library</title> <meta content="Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease - Rojas‐Reyes, MX - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008532.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease - Rojas‐Reyes, MX - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008532.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008532.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Combination inhaled steroid and long‐acting beta&lt;sub&gt;2&lt;/sub&gt;‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Maria Ximena Rojas‐Reyes" name="citation_author"/> <meta content="Pontificia Universidad Javeriana" name="citation_author_institution"/> <meta content="mxrojas@gmail.com" name="citation_author_email"/> <meta content="Olga M García Morales" name="citation_author"/> <meta content="Faculty of Medicine, Pontificia Universidad Javeriana" name="citation_author_institution"/> <meta content="Rodolfo J Dennis" name="citation_author"/> <meta content="Charlotta Karner" name="citation_author"/> <meta content="BMJ" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD008532.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/06/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008532.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008532.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008532.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Adrenergic beta‐2 Receptor Agonists [*administration &amp; dosage]; Bronchodilator Agents [*administration &amp; dosage]; Drug Therapy, Combination [methods]; Glucocorticoids [*administration &amp; dosage]; Pulmonary Disease, Chronic Obstructive [*drug therapy, mortality]; Randomized Controlled Trials as Topic; Tiotropium Bromide [*administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008532.pub3&amp;doi=10.1002/14651858.CD008532.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="afU96cMv";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008532\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008532\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008532.pub3",title:"Combination inhaled steroid and long\\u2010acting beta\u003csub\u003e2\u003c/sub\u003e\\u2010agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease",firstPublishedDate:"Jun 6, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008532.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008532.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008532.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008532.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008532.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008532.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008532.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008532.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008532.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008532.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1909 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008532.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-sec-0105"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-sec-0038"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-sec-0039"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-sec-0063"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-sec-0097"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/appendices#CD008532-sec-0110"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/table_n/CD008532StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/table_n/CD008532StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Combination inhaled steroid and long‐acting beta<sub>2</sub>‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/information#CD008532-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Maria Ximena Rojas‐Reyes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/information#CD008532-cr-0003">Olga M García Morales</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/information#CD008532-cr-0004">Rodolfo J Dennis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008532.pub3/information#CD008532-cr-0005">Charlotta Karner</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/information/en#CD008532-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 June 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008532.pub3">https://doi.org/10.1002/14651858.CD008532.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008532-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008532-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008532-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008532-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008532-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008532-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008532-abs-0001" lang="en"> <section id="CD008532-sec-0001"> <h3 class="title" id="CD008532-sec-0001">Background</h3> <p>The long‐acting bronchodilator tiotropium and single‐inhaler combination therapy of inhaled corticosteroids and long‐acting beta<sub>2</sub>‐agonists (ICS/LABA) are commonly used for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Combining these treatments, which have different mechanisms of action, may be more effective than administering the individual components. </p> </section> <section id="CD008532-sec-0002"> <h3 class="title" id="CD008532-sec-0002">Objectives</h3> <p>To assess relative effects of the following treatments on markers of exacerbations, symptoms, quality of life and lung function in patients with COPD. </p> <p>• Tiotropium plus LABA/ICS versus tiotropium.</p> <p>• Tiotropium plus LABA/ICS versus LABA/ICS.</p> </section> <section id="CD008532-sec-0003"> <h3 class="title" id="CD008532-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register of Trials (April 2015), ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>), the World Health Organization (WHO) trials portal and reference lists of relevant articles. </p> </section> <section id="CD008532-sec-0004"> <h3 class="title" id="CD008532-sec-0004">Selection criteria</h3> <p>We included parallel, randomised controlled trials (RCTs) lasting three months or longer conducted to compare ICS and LABA combination therapy in addition to inhaled tiotropium versus tiotropium alone or combination therapy alone. </p> </section> <section id="CD008532-sec-0005"> <h3 class="title" id="CD008532-sec-0005">Data collection and analysis</h3> <p>We independently assessed trials for inclusion, then extracted data on trial quality and outcome results. We contacted study authors to ask for additional information. We collected trial information on adverse effects. </p> </section> <section id="CD008532-sec-0006"> <h3 class="title" id="CD008532-sec-0006">Main results</h3> <p><b>Tiotropium plus LABA/ICS versus tiotropium</b> </p> <p>We included six studies (1902 participants) with low risk of bias that compared tiotropium in addition to inhaled corticosteroid and long‐acting beta2‐agonist combination therapy versus tiotropium alone. We found no statistically significant differences in mortality between treatments (odds ratio (OR) 1.80, 95% confidence interval (CI) 0.55 to 5.91; two studies; 961 participants) as well as in the all‐cause hospitalisations (OR 0.84, 95% CI 0.53 to 1.33; two studies; 961 participants). The effect on exacerbations was heterogeneous among trials and was not meta‐analysed. Health‐related quality of life measured by St. George’s Respiratory Questionnaire (SGRQ) showed a statistically significant improvement in total scores with use of tiotropium + LABA/ICS compared with tiotropium alone (mean difference (MD) ‐3.46, 95% CI ‐5.05 to ‐1.87; four studies; 1446 participants). Lung function was significantly different in the combined therapy (tiotropium + LABA/ICS) group, although average benefit with this therapy was small. None of the included studies included exercise tolerance as an outcome. </p> <p>A pooled estimate of these studies did not show a statistically significant difference in adverse events (OR 1.16, 95% CI 0.92 to 1.47; four studies; 1363 participants), serious adverse events (OR 0.86, 95% CI 0.57 to 1.30; four studies; 1758 participants) and pneumonia (Peto OR 1.62, 95% CI 0.54 to 4.82; four studies; 1758 participants). </p> <p><b>Tiotropium plus LABA/ICS versus LABA/ICS</b> </p> <p>One of the six studies (60 participants) also compared combined therapy (tiotropium + LABA/ICS) versus LABA/ICS therapy alone. This study was affected by lack of power; therefore results did not allow us to draw conclusions for this comparison. </p> </section> <section id="CD008532-sec-0007"> <h3 class="title" id="CD008532-sec-0007">Authors' conclusions</h3> <p>This review update includes three additional studies and provides new low quality evidence supporting the finding that tiotropium + LABA/ICS‐based therapy improves the disease‐specific quality of life. The current evidence is insufficient to support the benefit of tiotropium + LABA/ICS‐based therapy for mortality, hospital admission or exacerbations (moderate and low quality evidence). Compared with use of tiotropium alone, tiotropium + LABA/ICS‐based therapy does not seem to increase undesirable effects nor serious non‐fatal adverse events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008532-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008532-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008532-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008532-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008532-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008532-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008532-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008532-abs-0004" lang="en"> <h3>Are tiotropium plus combination inhalers better than tiotropium or combination inhalers alone for the treatment of COPD? </h3> <p><b>Background</b> </p> <p>Chronic obstructive pulmonary disease (COPD) is a lung disease that includes the conditions chronic bronchitis and/or emphysema. COPD is characterised by narrowing of the airways and lung tissue destruction. Symptoms include breathlessness and long‐term cough. Symptoms of COPD are treatable, but the condition cannot be reversed or cured. It is usually brought on by airway irritants, such as smoking or inhaled dust. </p> <p>Inhalers with bronchodilators (which allow the airways in the lungs to relax and expand) and/or anti‐inflammatory agents are commonly used to ease symptoms and minimise the long‐term decline in health caused by COPD. Examples of these treatments are tiotropium, which is a bronchodilator, and combination inhalers, which contain another type of bronchodilator (long‐acting beta‐agonists) together with anti‐inflammatory agents (steroids). These treatments work in different ways and therefore might be more beneficial if used together. </p> <p><b>Study characteristics</b> </p> <p>This review found six studies, involving 1902 participants, comparing the long‐term efficacy and side effects of tiotropium combined with combination inhalers for treatment of patients with COPD. Not all of the people included in these studies had COPD that was severe enough to be recommended for combined therapy according to current guidelines. </p> <p><b>Key results</b> </p> <p>Current evidence shows potential benefits of treatment with tiotropium in addition to inhaled corticosteroid and long‐acting beta2‐agonist combination therapy through increased health‐related quality of life and a small improvement i n lung function in patients receiving this combined therapy. However, this evidence does not allow us to draw conclusions about the effects of these treatments on mortality, hospitalisation for all causes and exacerbations. The frequency of serious and non‐serious adverse events was not increased in either of the two groups. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, we assessed the evidence presented in this review to be of moderate or low quality, which means we are reasonably confident in some of the findings, but less confident in others. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008532-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008532-sec-0105"></div> <h3 class="title" id="CD008532-sec-0106">Implications for practice</h3> <section id="CD008532-sec-0106"> <p>This review update includes three additional studies and provides new low quality evidence supporting the finding that tiotropium + LABA/ICS‐based therapy improves the disease‐specific quality of life but is insufficient to support the benefit of tiotropium + LABA/ICS‐based therapy for mortality, hospital admission or exacerbations (moderate and low quality evidence). Compared with use of tiotropium alone, tiotropium + LABA/ICS‐based therapy does not seem to increase undesirable effects nor serious non‐fatal adverse events. </p> </section> <h3 class="title" id="CD008532-sec-0107">Implications for research</h3> <section id="CD008532-sec-0107"> <p>Randomised controlled trials with complete follow‐up of 12 months are required to reduce uncertainty about the impact that tiotropium in combination with LABA/ICS might have on mortality and exacerbations when used as treatment for patients with COPD. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008532-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008532-sec-0029"></div> <div class="table" id="CD008532-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tiotropium + LABA/ICS combination compared with tiotropium for chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Tiotropium + LABA/ICS combination compared with tiotropium for chronic obstructive pulmonary disease </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with chronic obstructive pulmonary disease </p> <p><b>Settings:</b> ambulatory clinics </p> <p><b>Intervention</b>:tiotropium + LABA/ICS combination </p> <p><b>Comparison:</b> tiotropium </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> <p><b>Tiotropium</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> <p><b>Tiotropium + LABA/ICS combination</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality (all‐cause)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (5 to 47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.80<br/> (0.55 to 5.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>961<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admission (all causes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (69 to 145) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.84<br/> (0.53 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>961<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝ ⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation ‐ at 12‐month follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>628 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>601 per 1000<br/> (486 to 704) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.89<br/> (0.56 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (non‐fatal)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000<br/> (35 to 76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.86<br/> (0.57 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1758<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <sup>a,c</sup> <br/> Low </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life up to 6 months (SGRQ)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ up to 6 months in the intervention groups was 3.46 lower (5.05 to 1.87 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(4 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <sup>d</sup> <br/> Low </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A lower score indicates better quality of life</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> pre‐dose ‐ FEV<sub>1</sub> 3‐6 months mean difference </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean FEV<sub>1</sub> pre‐dose ‐ FEV<sub>1</sub> 3‐6 months mean difference in the intervention groups was 0.06 (0.04 to 0.08 ) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(4 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> pre‐dose ‐ FEV<sub>1</sub> 1 year </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean FEV<sub>1</sub> pre‐dose ‐ FEV<sub>1</sub> 1 year mean difference in the intervention groups was 0.06 (0 to 0.12 ) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>OR</b>: odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of imprecision (95% confidence interval includes both no effect and appreciable harm) </p> <p><sup>b</sup>Downgraded one level because of study limitations (incomplete outcome assessment in <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>) </p> <p><sup>c</sup>Downgraded once because of study limitations (incomplete outcome assessment in <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> and <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>; unclear risk of selection bias in <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>; possible detection bias in <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>) </p> <p><sup>d</sup>Downgraded two levels because of study limitations (unclear risk of selection bias and detection bias and incomplete outcome assessment in <a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a>; unclear risk of detection bias in <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>; incomplete outcome assessment in <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>) </p> <p><sup>e</sup>Downgraded one level because of study limitations (unclear risk of selection and detection bias in <a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>; unclear risk of detection bias in <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>; incomplete outcome assessment in <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008532-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008532-sec-0030"></div> <section id="CD008532-sec-0031"> <h3 class="title" id="CD008532-sec-0031">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is a general term that refers to chronic bronchitis or emphysema, or both. COPD occurs when airflow to the lungs is restricted by narrowing of the airways. Symptoms include cough, breathlessness and reduced exercise capacity. The Global Initiative for Chronic Obstructive Lung Disease (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>) guidelines describe COPD as a preventable and treatable condition that is not fully reversible. Worldwide, the main cause of COPD is tobacco smoking, but air pollution, burning of biomass and occupational exposure are also risk factors (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). The prevalence, morbidity and mortality of the disease vary across populations, and the disorder causes a substantial economic and social burden. </p> <p>Various pharmacological treatments are commonly used in COPD management to relieve symptoms, improve exercise tolerance and quality of life, reduce mortality and prevent and treat exacerbations. Exacerbations of COPD impair patients' quality of life, and a large part of the economic burden of COPD is attributed to the cost of managing exacerbations, particularly those resulting in the use of acute care services or hospitalisations (<a href="./references#CD008532-bbs2-0035" title="HutchinsonA , BrandC , IrvingL , RobertsC , ThompsonP , CampbellD . Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure. Internal Medical Journal2010;40(5):364‐71. [1445‐5994: (Electronic)] ">Hutchinson 2010</a>). Appropriate pharmacological management of the disease is therefore important to reduce and prevent exacerbations. Management of COPD tends to begin with one treatment, and additional therapies are introduced as necessary to control symptoms (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). Self‐management, education, vaccination and rehabilitation can accompany these pharmacological interventions (<a href="./references#CD008532-bbs2-0030" title="EffingT , MonninkhofEEM , van derValkPP , ZielhuisGGA , WaltersEH , van derPalenJJ , et al. Self‐management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD002990.pub2] ">Effing 2007</a>; <a href="./references#CD008532-bbs2-0038" title="LacasseY , GoldsteinR , LassersonTJ , MartinS . Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD003793.pub2] ">Lacasse 2006</a>; <a href="./references#CD008532-bbs2-0050" title="SehatzadehS . Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): an evidence‐based analysis. Ontario Health Technology Assessment Series2012;12(3):1‐64. [PUBMED: 3384373] ">Sehatzadeh 2012</a>). </p> </section> <section id="CD008532-sec-0032"> <h3 class="title" id="CD008532-sec-0032">Description of the intervention</h3> <p>The first pharmacological step in treating patients with COPD consists of the use of short‐acting bronchodilators for symptom control when needed. These include short‐acting beta<sub>2</sub>‐agonists (SABA) and the short‐acting anticholinergic agent ipratropium. To manage persistent COPD symptoms, long‐acting bronchodilators can be introduced (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). Regular treatment with long‐acting bronchodilators is more efficient and convenient than treatment with regular short‐acting bronchodilators (<a href="./references#CD008532-bbs2-0025" title='BeehKM , BeierJ . The short, the long and the "ultra‐long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Advances in Therapy2010;27(3):150‐9. '>Beeh 2010</a>). Long‐acting bronchodilators include long‐acting beta<sub>2</sub>‐agonists (LABA) and the long‐acting anticholinergic agent tiotropium. Tiotropium bromide has gained widespread acceptance as once daily maintenance therapy in COPD (<a href="./references#CD008532-bbs2-0024" title="BarrRG , BourbeauJ , CamargoCA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>; <a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). Tiotropium reduces COPD exacerbations and related hospitalisations compared with ipratropium (<a href="./references#CD008532-bbs2-0024" title="BarrRG , BourbeauJ , CamargoCA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>). Most LABA are taken twice daily. They improve lung function compared with ipratropium, but little difference is shown in improving COPD symptoms and exercise tolerance (<a href="./references#CD008532-bbs2-0023" title="AppletonS , JonesT , PooleP , PilottoL , AdamsR , LassersonTJ , et al. Ipratropium bromide versus long‐acting beta‐2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD006101] ">Appleton 2006</a>). For symptomatic patients with severe or very severe COPD (forced expiratory volume in one second (FEV<sub>1</sub>) &lt; 50% predicted) and with repeated exacerbations, <a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a> recommends the addition of inhaled corticosteroids (ICS) to bronchodilator treatment. Inhaled corticosteroids are licensed as combination inhalers with LABA. The most common combinations of ICS and LABA in combination inhalers are fluticasone and salmeterol; budesonide and formoterol; and mometasone and formoterol. Combination therapy reduces exacerbation rates and mortality compared with ICS alone (<a href="./references#CD008532-bbs2-0046" title="NanniniLJ , PooleP , MilanSJ , HolmesR , NormansellR . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD003794.pub4] ">Nannini 2013</a>). Also compared with LABA alone, combination therapy is more effective in reducing exacerbation rates, but with no significant difference in mortality (<a href="./references#CD008532-bbs2-0045" title="NanniniLJ , CatesCJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta‐agonist in one inhaler versus long‐acting beta‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub2] ">Nannini 2007b</a>). For patients who continue to have symptoms and are at high risk of experiencing exacerbations, triple therapy with LABA, long‐acting muscarinic antagonists (LAMA, e.g. tiotropium) and ICS is recommended. Such patients are referred to as 'Group D' in the GOLD guidelines; this group typically includes patients classified as GOLD 3 and 4, i.e. FEV<sub>1</sub> &lt; 50% of predicted value (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). Benefits of combination inhalers should be viewed against the possible increased risk of pneumonia (<a href="./references#CD008532-bbs2-0045" title="NanniniLJ , CatesCJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta‐agonist in one inhaler versus long‐acting beta‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub2] ">Nannini 2007b</a>; <a href="./references#CD008532-bbs2-0046" title="NanniniLJ , PooleP , MilanSJ , HolmesR , NormansellR . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD003794.pub4] ">Nannini 2013</a>). Potential risks and benefits of treatment with combination inhaler compared with tiotropium are uncertain (<a href="./references#CD008532-bbs2-0051" title="WelshEJ , CatesCJ , PooleP . Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2010, Issue 5. [DOI: 10.1002/14651858.CD007891.pub2] ">Welsh 2010</a>), as are risks and benefits of treatment with combination inhaler in addition to tiotropium, which will be explored in this review. </p> </section> <section id="CD008532-sec-0033"> <h3 class="title" id="CD008532-sec-0033">How the intervention might work</h3> <section id="CD008532-sec-0034"> <h4 class="title">Tiotropium</h4> <p>Tiotropium (TIO) is a long‐acting anticholinergic agent that targets bronchospasm in COPD by relaxing the smooth muscle of the airways. Tiotropium is structurally related to ipratropium, a short‐acting anticholinergic agent that binds to M1, M2 and M3 muscarinic receptors, which in turn open the bronchi (<a href="./references#CD008532-bbs2-0024" title="BarrRG , BourbeauJ , CamargoCA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>). Although tiotropium binds to the same receptors as ipratropium, it has different kinetic selectivity. Tiotropium dissociates slowly from M1 and M3 receptors, giving a bronchodilator effect lasting over 24 hours, but rapidly from M2 receptors. It appears that M2 receptors are feedback inhibitory receptors, and blocking them (as is the case for ipratropium) releases acetylcholine rather than reducing it as desired (<a href="./references#CD008532-bbs2-0024" title="BarrRG , BourbeauJ , CamargoCA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>). Benefits of tiotropium, in comparison with placebo, include reduced COPD exacerbations and exacerbation‐related hospitalisations, and improved health‐related quality of life and symptom scores among patients with moderate and severe disease (<a href="./references#CD008532-bbs2-0024" title="BarrRG , BourbeauJ , CamargoCA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>). Anticholinergic side effects can occur with tiotropium and include dry mouth, constipation and tachycardia. </p> </section> <section id="CD008532-sec-0035"> <h4 class="title">Inhaled beta<sub>2</sub>‐agonist plus inhaled corticosteroids </h4> <p>Inhaled beta<sub>2</sub>‐agonists activate beta<sub>2</sub>‐receptors in the smooth muscle of the airways, releasing adenylate cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP), which leads to a cascade of reactions resulting in bronchodilation. Beta<sub>2</sub>‐agonists may act through other mechanisms such as respiratory muscle function or mucociliary clearance; patients have shown improvement in symptoms whilst showing no improvement in lung function tests. Beta<sub>2</sub>‐agonists are particularly useful because they reverse bronchoconstriction regardless of its initial cause. Side effects include muscle tremors, nervousness and occasional insomnia, but, as with all inhaled medications, systemic side effects are minimised by a comparatively low dose administered directly to the lungs. Inhaled corticosteroids are anti‐inflammatory drugs that have been associated with reduced risk of exacerbation in patients with COPD and with better quality of life outcomes when compared with placebo, with no effect on overall mortality or long‐term FEV<sub>1</sub> (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>; <a href="./references#CD008532-bbs2-0053" title="YangIA , ClarkeMS , SimEHA , FongKM . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3] ">Yang 2012</a>). Combination inhalers including ICS and LABA reduce exacerbation rates and all‐cause mortality and improve lung function and quality of life compared with placebo (<a href="./references#CD008532-bbs2-0044" title="NanniniL , CatesCJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub2] ">Nannini 2007a</a>). These effects are thought to be greater for combination inhalers than for the component preparations (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). Use of inhaled corticosteroids, alone or in combination with beta<sub>2</sub>‐agonists, potentially increases the risk of pneumonia (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>; <a href="./references#CD008532-bbs2-0053" title="YangIA , ClarkeMS , SimEHA , FongKM . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3] ">Yang 2012</a>). </p> <p>The combination inhalers currently available are fluticasone/salmeterol (FSC); budesonide/formoterol (BUD/F); and beclomethasone/formoterol (DPB/F). </p> </section> <section id="CD008532-sec-0036"> <h4 class="title">Combination therapy</h4> <p>The nature of the interaction between the two systems is not yet fully understood, but combining beta<sub>2</sub>‐adrenergic receptor agonists and muscarinic acetylcholine receptor antagonists is pharmacologically reasonable, given that airway tone is regulated by the parasympathetic and sympathetic nervous systems. The synergistic effect of these therapies can be explained in several ways. One explanation is that the addition of a beta<sub>2</sub>‐adrenergic receptor agonist decreases release of acetylcholine (ACh) and amplifies bronchial smooth muscle relaxation; another is that the addition of a muscarinic acetylcholine receptor antagonist can reduce bronchoconstrictor effects of ACh and amplify bronchodilation through direct stimulation of the smooth muscle beta<sub>2</sub>‐adrenergic receptor (<a href="./references#CD008532-bbs2-0028" title="CazzolaM , MolimardM . The scientific rationale for combining long‐acting b2‐agonists and muscarinic antagonists in COPD. Pulmonary Pharmacology &amp; Therapeutics2010;23(4):257‐67. [DOI: 10.1016/j.pupt.2010.03.003] ">Cazzola 2010</a>). An animal model showed activation of calcium‐activated potassium (KCa) channels thought to hyperpolarise the cell membrane, causing reductions in the concentration of intracellular calcium (Ca) and ACh release in prejunctional cholinergic nerves (<a href="./references#CD008532-bbs2-0026" title="BrichettoL , SongP , CrimiE . Modulation of cholinergic responsiveness through the [beta]‐adrenoceptor signal transmission pathway in bovine trachealis. Journal of Applied Physiology2003;95(2):735‐41. ">Brichetto 2003</a>). </p> </section> </section> <section id="CD008532-sec-0037"> <h3 class="title" id="CD008532-sec-0037">Why it is important to do this review</h3> <p>The previous version of this review showed a significant effect of combination therapy tiotropium + LABA/ICS on FEV<sub>1</sub> in participants with stable COPD, in comparison with tiotropium therapy alone. However, sparse evidence was found to support similar beneficial effects on other important outcomes, such as all‐cause hospitalisations, exacerbations and mortality. New published trials have been conducted with the aim of comparing these therapies; therefore it is necessary to include their results as part of this review to obtain more precise estimations of treatment effects on outcomes for which combination therapy effects remain unclear. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008532-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008532-sec-0038"></div> <p>To assess relative effects of the following treatments on markers of exacerbations, symptoms, quality of life and lung function in patients with COPD. </p> <p> <ul id="CD008532-list-0001"> <li> <p>Tiotropium plus LABA/ICS versus tiotropium.</p> </li> <li> <p>Tiotropium plus LABA/ICS versus LABA/ICS.</p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008532-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008532-sec-0039"></div> <section id="CD008532-sec-0040"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008532-sec-0041"> <h4 class="title">Types of studies</h4> <p>For effectiveness and safety objectives, we included randomised controlled trials (RCTs) of parallel design conducted in patients with stable COPD who received the trial treatment for at least 12 weeks. </p> <p>For economic objectives, we included economic evaluation studies such as cost‐effectiveness analyses and cost‐utility analyses addressing the same interventions in the population of interest for this review. We considered for inclusion the economic evaluation conducted alongside the RCT or economic evaluation modelling studies based on a comprehensive systematic review of the literature. We excluded partial economic evaluation studies reporting cost analysis or cost‐outcome descriptions. </p> </section> <section id="CD008532-sec-0042"> <h4 class="title">Types of participants</h4> <p>Populations with a diagnosis of COPD. We included only studies that used an external set of criteria to screen participants for this condition (e.g. <a href="http://www.thoracic.org/sections/copd/index.html" target="_blank">ATS</a>; <a href="http://www.thoracic.org/sections/copd/index.html" target="_blank">BTS</a>; <a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>; <a href="http://www.copdx.org.au/guidelines/a_copd_guidelines.asp" target="_blank">TSANZ</a>). </p> </section> <section id="CD008532-sec-0043"> <h4 class="title">Types of interventions</h4> <p>Inhaled combination corticosteroid and long‐acting beta<sub>2</sub>‐agonist (such as fluticasone/salmeterol, budesonide/formoterol, beclomethasone/formoterol) and tiotropium bromide versus: </p> <p> <ul id="CD008532-list-0002"> <li> <p>inhaled tiotropium bromide alone; or</p> </li> <li> <p>inhaled corticosteroid and long‐acting beta<sub>2</sub>‐agonist combination. </p> </li> </ul> </p> </section> <section id="CD008532-sec-0044"> <h4 class="title">Types of outcome measures</h4> <section id="CD008532-sec-0045"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008532-list-0003"> <li> <p>Mortality (all‐cause).</p> </li> <li> <p>Exercise tolerance.</p> </li> <li> <p>Hospital admissions: all‐cause and due to exacerbations.</p> </li> <li> <p>Exacerbations: all‐cause, requiring short burst oral corticosteroids or antibiotics as defined by agreed criteria. </p> </li> <li> <p>Health‐related quality of life (measured with a validated scale for COPD, e.g. St George's Respiratory Questionnaire (SGRQ), Chronic Respiratory Disease Questionnaire (CRQ)). </p> </li> <li> <p>Serious adverse events non‐fatal.</p> </li> <li> <p>Pneumonia.</p> </li> </ul> </p> </section> <section id="CD008532-sec-0046"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008532-list-0004"> <li> <p>Symptoms.</p> </li> <li> <p>Forced expiratory volume in one second (FEV<sub>1</sub>). </p> </li> <li> <p>Adverse events.</p> </li> <li> <p>Side effects.</p> </li> <li> <p>Cost‐effectiveness of interventions.</p> </li> </ul> </p> </section> </section> </section> <section id="CD008532-sec-0047"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008532-sec-0048"> <h4 class="title">Electronic searches</h4> <p>The previously published version of this review (<a href="./references#CD008532-bbs2-0054" title="KarnerC , CatesCJ . Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD008532.pub2] ">Karner 2011</a>) included searches up to July 2010. The search period for this update is July 2010 to April 2015. </p> <p>For this update, we identified trials from the Cochrane Airways Group Specialised Register (CAGR), which is maintained by the Information Specialist for the Group. The Register contains trial reports identified through systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Allied and Complementary Medicine Database (AMED) and PsycINFO, and by handsearching of respiratory journals and meeting abstracts (please see <a href="./appendices#CD008532-sec-0111">Appendix 1</a> for further details). We searched all records in the CAGR using the search strategy provided in <a href="./appendices#CD008532-sec-0117">Appendix 2</a>. </p> <p>We also conducted a search of ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>) and the World Health Organization (WHO) trials portal (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>). We searched all databases from their inception to the present, with no restriction on the language of publication. We conducted the latest search in April 2015. </p> </section> <section id="CD008532-sec-0049"> <h4 class="title">Searching other resources</h4> <p>We reviewed reference lists of all primary studies and review articles for additional references. We contacted authors of identified trials and asked them to identify other published or unpublished studies. </p> </section> </section> <section id="CD008532-sec-0050"> <h3 class="title" id="CD008532-sec-0050">Data collection and analysis</h3> <section id="CD008532-sec-0051"> <h4 class="title">Selection of studies</h4> <p>Two review authors (OMG and RJD) screened the titles and abstracts of citations retrieved through literature searches and obtained those deemed to be potentially relevant. We assigned each reference to a study identifier and assessed all references against the inclusion criteria of the protocol. </p> <p>Two review authors (OMG and RJD) independently examined titles and abstracts for the selection of health economics studies to be included in the critical review of economic data. We removed records that did not report on cost‐effectiveness or cost‐utility analysis. Two review authors (MXR and RJD) independently examined full‐text reports to determine which studies met the eligibility criteria of this review. We resolved disagreements by discussion between review authors. We included only full economic evaluations of high methodological and reporting quality. </p> </section> <section id="CD008532-sec-0052"> <h4 class="title">Data extraction and management</h4> <p>We extracted the following characteristic information from each study.</p> <p> <ul id="CD008532-list-0005"> <li> <p>Design (design, total duration of study and run‐in, number of study centres and locations, withdrawals, date of study). </p> </li> <li> <p>Participants (N, mean age, age range, gender, COPD severity, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, exclusion criteria). </p> </li> <li> <p>Interventions (run‐in, intervention treatment and inhaler type, control treatment and inhaler type). </p> </li> <li> <p>Outcomes (primary and secondary outcomes specified and collected, time points reported).</p> </li> </ul> </p> <p>Two review authors (MXR and OMG) extracted data from the studies onto data collection forms. Review authors discussed discrepancies in the data and resolved them and transferred data from data collection forms into RevMan (<a href="./references#CD008532-bbs2-0048" title="Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan). Version 5.3.5. Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>Data obtained by authors from the previous version of this review regarding all cause hospital admissions that were supplied by Aaron 2007 and by AstraZeneca (for Welte 2009) on request, were kept for this update without changes. </p> </section> <section id="CD008532-sec-0053"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed all included studies for risk of bias according to the recommendations outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008532-bbs2-0034" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org (accessed 11 June 2015). ">Higgins 2011</a>) for the following items. </p> <p> <ul id="CD008532-list-0006"> <li> <p>Allocation sequence generation.</p> </li> <li> <p>Concealment of allocation.</p> </li> <li> <p>Blinding of participants and investigators.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> </ul> </p> <p>We noted other sources of bias and graded each potential source of bias as having high, low or unclear risk. </p> <p>We assessed the methodological quality of economic evaluations by using the Drummond checklist (<a href="./references#CD008532-bbs2-0029" title="DrummondMF , JeffersonTO . Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ1996;313:275‐83. [DOI: 10.1136/bmj.313.7052.275] ">Drummond 1996</a>), which addresses the following methodological and reporting aspects. </p> <p> <ul id="CD008532-list-0007"> <li> <p>Was a well‐defined question posed?</p> </li> <li> <p>Was a comprehensive description of competing alternatives given?</p> </li> <li> <p>Does the paper provide evidence that the programme would be effective (i.e. would the programme do more harm than good)? </p> </li> <li> <p>Were all important and relevant resource uses (costs) for each alternative identified?</p> </li> <li> <p>Were all important and relevant health outcome consequences for each alternative identified?</p> </li> <li> <p>Were costs measured accurately in appropriate units before evaluation and valued credibly?</p> </li> <li> <p>Were health outcome consequences measured credibly?</p> </li> <li> <p>Were costs and health outcome consequences adjusted for the different times at which they occurred (i.e. was discounting applied)? </p> </li> <li> <p>Was an incremental analysis of the consequences and costs of alternatives performed?</p> </li> <li> <p>Was an adequate sensitivity analysis performed?</p> </li> </ul> </p> <section id="CD008532-sec-0054"> <h5 class="title">Quality of the body of evidence for each outcome</h5> <p>We assessed the quality of evidence for the main comparison at the outcome level using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD008532-bbs2-0033" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383–94. ">Guyatt 2011</a>). This methodological approach considers RCTs as providing high‐quality evidence that may be rated down by limitations in any of five areas: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates and presence of publication bias (<a href="./references#CD008532-bbs2-0033" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383–94. ">Guyatt 2011</a>). The GRADE approach results in an assessment of the quality of a body of evidence in one of four grades: (1) high: We are very confident that the true effect lies close to that of the estimate of effect; (2) moderate: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different; (3) low: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect; (4) very low: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect (<a href="./references#CD008532-bbs2-0032" title="SchünemannH , BrożekJ , GuyattG , OxmanA . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. http://www.guidelinedevelopment.org/handbook/#h.buaodtl66dyx (accessed 11 June 2015). ">GRADE 2013</a>). </p> <p>Two review authors (OMG and MXR) independently assessed the quality of the body of evidence found for each of the outcomes identified as critical or important for clinical decision making: mortality, hospital admission (all causes), exacerbation at 12 months, improvement in FEV<sub>1</sub>, serious adverse events and quality of life. In the case that the study authors did not take measures to ensure concealment of allocation, randomised assignment, completion to follow‐up or blinded outcome assessment, we downgraded the quality of evidence because of design limitations (<a href="./references#CD008532-bbs2-0032" title="SchünemannH , BrożekJ , GuyattG , OxmanA . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. http://www.guidelinedevelopment.org/handbook/#h.buaodtl66dyx (accessed 11 June 2015). ">GRADE 2013</a>). We evaluated consistency by similarity of point estimates, extent of overlap of confidence intervals (CIs) and application of statistical criteria including testing for heterogeneity (I<sup>2</sup>). We planned to downgrade the quality of evidence if we detected substantial unexplained heterogeneity across study results (i.e. some studies suggest important benefit and others no effect or harm without a clinical explanation) (<a href="./references#CD008532-bbs2-0032" title="SchünemannH , BrożekJ , GuyattG , OxmanA . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. http://www.guidelinedevelopment.org/handbook/#h.buaodtl66dyx (accessed 11 June 2015). ">GRADE 2013</a>). We assessed precision according to the 95% CI around the pooled estimate (<a href="./references#CD008532-bbs2-0032" title="SchünemannH , BrożekJ , GuyattG , OxmanA . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. http://www.guidelinedevelopment.org/handbook/#h.buaodtl66dyx (accessed 11 June 2015). ">GRADE 2013</a>). When studies were conducted in populations other than the target population, the GRADE framework suggests that the quality of evidence should be downgraded because of indirectness (<a href="./references#CD008532-bbs2-0032" title="SchünemannH , BrożekJ , GuyattG , OxmanA . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. http://www.guidelinedevelopment.org/handbook/#h.buaodtl66dyx (accessed 11 June 2015). ">GRADE 2013</a>).  </p> <p>We entered data (i.e. pooled estimates of effects and corresponding 95% CIs) and explicit judgements that were made for each of the above aspects into the GRADEprofiler (GDT), the software used to create Summary of findings (SoF) tables. We explained in the SoF table footnotes all judgements involved in assessment of the aspects of the evidence described above. </p> </section> </section> <section id="CD008532-sec-0055"> <h4 class="title">Measures of treatment effect</h4> <p>We performed all statistical analyses using RevMan software (<a href="./references#CD008532-bbs2-0048" title="Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan). Version 5.3.5. Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We analysed dichotomous data (such as mortality, hospital admission, number of participants with one or more exacerbations) using the Mantel‐Haenszel odds ratio (OR) and risk difference (RD), unless events were rare, in which case we employed the Peto OR (as this does not require a continuity correction for zero cells). For statistically significant results of categorical variables, we reported the number needed to treat for an additional beneficial outcome (NNTB). </p> <p>We analysed continuous outcome data (such as quality of life (score) and FEV<sub>1</sub>) using the mean difference (MD). We reported the 95% CI on all estimates as fixed‐effect mean differences with 95% CI. When treatment effects were reported as a mean difference with 95% CI, we entered the MD and standard errors calculated from the 95% CI and analysed data using the generic inverse variance (GIV) tool. </p> </section> <section id="CD008532-sec-0056"> <h4 class="title">Unit of analysis issues</h4> <p>We analysed dichotomous data by using participants as the unit of analysis (rather than events) to avoid counting the same participant more than once. </p> </section> <section id="CD008532-sec-0057"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators and study sponsors to verify key study characteristics and to obtain missing numerical outcome data. </p> </section> <section id="CD008532-sec-0058"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the amount of statistical variation between study results by using the I<sup>2</sup> measurement. </p> </section> <section id="CD008532-sec-0059"> <h4 class="title">Assessment of reporting biases</h4> <p>We minimised reporting bias from non‐publication of studies or selective outcome reporting by using a broad search strategy, by contacting study authors directly and by checking references of included studies. We planned to assess reporting bias by visual inspection of funnel plots. </p> </section> <section id="CD008532-sec-0060"> <h4 class="title">Data synthesis</h4> <p>We combined dichotomous data using the Mantel‐Haenszel OR with 95% CIs by using a fixed‐effect model. We combined rate ratios and hazard ratios using GIV in a fixed‐effect model and compared them with the random‐effects model. We planned to calculate the NNTB outcome from the pooled OR and its CI, and to apply appropriate levels of baseline risk. We have presented the findings of our primary outcomes in <a href="./full#CD008532-tbl-0001">summary of findings Table for the main comparison</a>, which we generated by using <a href="http://www.gradeworkinggroup.org/" target="_blank">GradePro</a> software. </p> <p>We did not perform pooled calculations of economic data. Rather, we presented the characteristics and results of included economic studies in a descriptive way in the additional tables (<a href="#CD008532-tbl-0002">Table 1</a>; <a href="#CD008532-tbl-0003">Table 2</a>), including the final incremental cost‐effectiveness ratios (ICERs) reported by study authors in Euros (EUR). We did not adjust the values of ICERs provided by study authors because most identified studies were conducted in similar settings and during a similar time period (2009 to 2010) using the same information resource, as all are based on the same clinical trial data. </p> <div class="table" id="CD008532-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included economic evaluations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Population</b> </p> <p><b> (N participants, severity indicators, smoking history</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Economic outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Intervention<sup>a</sup> (doses)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Perspective</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Price year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Time horizon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> ICER reported and adjusted to Euros 2014</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0043" title="NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. ">Najafzadeh 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cost utility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Based on the <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> study: </p> <p>N = 449, patients with ≥ 1 exacerbation within 12 months, moderate and severe obstruction defined as FEV<sub>1</sub> &lt; 65% post‐bronchodilator, ≥ 10 pack‐years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incremental cost per exacerbation avoided and incremental cost per QALY with tiotropium + LABA/ICS relative to tiotropium </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>• Tiotropium 18 mcg once daily + placebo twice daily</p> <p>• Tiotropium 18 mcg once daily + FS 250/25 mg/puff, 2 puffs twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Healthcare</p> <p>system perspective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per exacerbation avoid CAN$6510</p> <p>Per QALY CAN$243180</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0042" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] ">Mittmann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia, Canada and Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Based on the <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> study: </p> <p>N = 659, aged ≥ 40 years, symptoms for ≥ 2 years, ≥ 1 exacerbation within 12 months requiring systemic steroids and/or antibiotics, FEV<sub>1</sub> ≤ 50% of predicted normal, FEV<sub>1</sub> /FVC &lt; 70% pre‐dose, ≥ 10 pack‐years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incremental cost‐effectiveness ratio for exacerbation avoided with tiotropium + LABA/ICS relative to tiotropium </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>• Tiotropium (Handihaler) 18 mcg once daily + budesonide/formoterol (Symbicort Turbuhaler) 320/9 mcg one inhalation twice daily </p> <p>• Tiotropium 18 mcg once daily + placebo (identical Turbuhaler) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Healthcare system payer perspective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per avoiding severe exacerbation: Australia: tiotropium + LABA/ICS dominant</p> <p>Canadian:</p> <p>tiotropium + LABA/ICS dominant</p> <p>Sweden:</p> <p>244,36 EUR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0047" title="NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] ">Nielsen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark, Finland, Norway and Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Based on the <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> study: </p> <p>N = 659, aged ≥ 40 years, clinical diagnosis of COPD and symptoms ≥ 2 years, ≥ 1 exacerbation in the previous 12 months requiring systemic steroids and/or antibiotics, FEV<sub>1</sub> ≤ 50% predicted normal value, FEV<sub>1</sub> /FVC &lt; 70% pre‐dose, ≥10 pack‐years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incremental cost‐effectiveness ratio for exacerbation avoided with tiotropium + LABA/ICS relative to tiotropium </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>• Tiotropium (Handihaler) 18 mcg once daily + budesonide/formoterol (Symbicort Turbuhaler) 320/9 mcg one inhalation twice daily </p> <p>• Tiotropium 18 mcg once daily + placebo (identical Turbuhaler) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Healthcare system payer perspective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICER excluding antibiotics Denmark:</p> <p>212 EUR</p> <p>Finland:</p> <p>307 EUR</p> <p>Norway:</p> <p>tiotropium + LABA/ICS dominant</p> <p>Sweden:</p> <p>165 EUR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Tiotropium was compared with tiotropium + budesonide/formoterol in all included economic evaluations. </p> <p>CEA: cost‐effectiveness analysis</p> <p>FEV<sub>1</sub>: forced expiratory volume in one second </p> <p>FVC: forced vital capacity</p> <p>ICER: incremental cost‐effectiveness ratio</p> <p>ICS: inhaled corticosteroids</p> <p>LABA: long‐acting beta‐agonists</p> <p>QALY: quality‐adjusted life‐year</p> </div> </div> <div class="table" id="CD008532-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Quality assessment of included economic evaluations (Drummond checklist)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Well‐defined question?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Competing alternatives described?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Effectiveness established?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Relevant costs and consequences identified?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Costs and consequences measured accurately?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Costs and consequences valued credibly?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Discounting performed?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Incremental analysis of costs and consequences performed?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Sensitivity analysis performed?</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0042" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] ">Mittmann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0043" title="NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. ">Najafzadeh 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0047" title="NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] ">Nielsen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD008532-sec-0061"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analyses for effectiveness and safety data on the basis of types of combination therapy and differences in baseline risk (severity of disease at baseline), provided at least three studies per subgroup were included in a specific comparison. However, included studies did not provide data for these subgroup analyses. Included studies reported outcomes at different follow‐up periods, and different follow‐periods may be associated with different treatment effects; therefore, we decided to include three subgroup analyses: at three‐month follow‐up; at six‐month follow‐up; and at 12‐month follow‐up. </p> </section> <section id="CD008532-sec-0062"> <h4 class="title">Sensitivity analysis</h4> <p>The sensitivity analysis takes into account biases that could significantly impact the outcomes of included studies. We planned to perform a sensitivity analysis to assess how results of the meta‐analysis would be affected by excluding studies determined to be at a high risk of bias. Two studies (<a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a>; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>) were open‐label studies; therefore we performed a sensitivity analysis for outcomes of quality of life (QoL) and for all severe adverse events (non‐fatal). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008532-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008532-sec-0063"></div> <section id="CD008532-sec-0064"> <h3 class="title">Description of studies</h3> <section id="CD008532-sec-0065"> <h4 class="title">Results of the search</h4> <p>The initial search carried out in July 2010 yielded 101 references, from which only three studies (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>) were included and one RCT was classified as awaiting assessment (<a href="./references#CD008532-bbs2-0019" title="FangL , LiangX , ZhangF , LiuL , FuW , ZhaoZ , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Zhonghua Jiehe He Huxi Zazhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2008;31(11):811‐4. ">Fang 2008</a>). Details of the search results from the previous review are described in <a href="./appendices#CD008532-sec-0118">Appendix 3</a>. We updated these searches in April 2015 and identified 250 new references from July 2010. Of these, 13 references were selected as potentially relevant and underwent full‐text review. Three new studies (<a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>; <a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a>; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>) and three economic analyses (<a href="./references#CD008532-bbs2-0042" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] ">Mittmann 2011</a>; <a href="./references#CD008532-bbs2-0043" title="NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. ">Najafzadeh 2008</a>; <a href="./references#CD008532-bbs2-0047" title="NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] ">Nielsen 2013</a>) met the criteria for inclusion, two RCTs were classified as ongoing studies (<a href="./references#CD008532-bbs2-0021" title="BetsuyakuT , KatoM . A study to assess COPD symptom‐based management and to optimise treatment strategy in Japan (COSMOS‐J) based on GOLD 2011. International Journal of Chronic Obstructive Pulmonary Disease2013;8:453‐9. [DOI: 10.2147/COPD.S48298] ">Betsuyaku 2013</a>; <a href="./references#CD008532-bbs2-0022" title="CohuetGeraldine . A study to compare the effect of inhaled treatments: the combination of 3 components (beclometasone/formoterol/glycopyrrolate) to a known single treatment (tiotropium) or the double combination of tiotropium (Spiriva) and beclometasone plus formoterol in patients with chronic obstructive pulmonary disease treated for one year.. The European Union Clinical Trials Register 2013‐10‐11. [EudraCT Number:2013‐000063‐91] ">Cohuet 2013</a>) and one RCT was classified as awaiting assessment (<a href="./references#CD008532-bbs2-0020" title="">Lee 2014</a>) because only results from the abstract presented at a scientific meeting were available. We excluded four studies (see the <a href="#CD008532-sec-0069">Excluded studies</a> section). We did not find published results of the <a href="./references#CD008532-bbs2-0019" title="FangL , LiangX , ZhangF , LiuL , FuW , ZhaoZ , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Zhonghua Jiehe He Huxi Zazhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2008;31(11):811‐4. ">Fang 2008</a> study for this review; therefore, it is still awaiting assessment. </p> <p>In summary, for the clinical effectiveness objective we included a total of six studies (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>; <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>; <a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a>; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>), randomising 1902 participants to comparisons of interest for the review. We included three studies (<a href="./references#CD008532-bbs2-0042" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] ">Mittmann 2011</a>; <a href="./references#CD008532-bbs2-0043" title="NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. ">Najafzadeh 2008</a>; <a href="./references#CD008532-bbs2-0047" title="NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] ">Nielsen 2013</a>) for the economic evaluation objective related to cost‐effectiveness (<a href="#CD008532-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD008532-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008532-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008532-sec-0066"> <h4 class="title">Included studies</h4> <section id="CD008532-sec-0067"> <h5 class="title">Randomised controlled trials (RCTs)</h5> <p>We included a total of six RCTs in this review. All included studies (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>; <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>; <a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a>; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>) assessed the effectiveness of tiotropium plus LABA/ICS in comparison with tiotropium, and just one study (<a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>) also compared the effectiveness of tiotropium plus LABA/ICS versus LABA/ICS (see the <a href="./references#CD008532-sec-0133" title="">Characteristics of included studies</a> table and <a href="#CD008532-tbl-0004">Table 3</a>). Not all of the participants enrolled in the included studies were eligible for triple therapy according to the current guidance (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). </p> <div class="table" id="CD008532-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included studies: baseline COPD severity and exacerbation status</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline COPD severity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline FEV<sub>1</sub>% predicted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Exacerbation status preceding enrolment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inclusion criteria &lt; 65% predicted</p> <p>Mean FEV<sub>1</sub>% predicted tiotropium + LABA/ICS group 42.2% and in tiotropium group 42.1% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Required to have had ≥ 1 exacerbation in previous year</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe and very severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inclusion criteria ≤ 50% predicted</p> <p>Mean FEV<sub>1</sub>% predicted LABA/ICS group = 36.9%, tiotropium group = 38.5%, tiotropium + LABA/ICS group = 39% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information on exacerbation status before enrolment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate: tiotropium + LABA/ICS = 63% and tiotropium = 72%</p> <p>Severe: tiotropium + LABA/ICS = 37% and tiotropium = 28%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inclusion criteria ≥ 40 to ≤ 80% predicted</p> <p>Mean FEV<sub>1</sub>% predicted tiotropium + LABA/ICS group = 56% and tiotropium group = 57.4% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations in past 12 months requiring antibiotics/corticosteroid: tiotropium + LABA/ICS: 1 exacerbation = 37%, ≥ 2 exacerbations = 6% </p> <p>Tiotropium: 1 exacerbation = 27%, ≥ 2 exacerbations = 6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to very severe</p> <p>Overall: mild = 10%, moderate = 33%, severe = 36.6%, very severe = 20%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean FEV<sub>1</sub>% predicted tiotropium + LABA/ICS group = 64.6% and tiotropium group = 57.1% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants were excluded if they had experienced an exacerbation in the previous 12 weeks before commencement of the study. No other information on exacerbation status </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate: tiotropium + LABA/ICS = 56.6% and tiotropium = 60.3%</p> <p>Severe: tiotropium + LABA/ICS = 40.8% and tiotropium = 35.5%</p> <p>Very severe: tiotropium + LABA/ICS = 2.7% and tiotropium = 3.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inclusion criteria &lt; 65% predicted</p> <p>Mean FEV<sub>1</sub>% predicted tiotropium + LABA/ICS group = 47.4% and tiotropium group = 47.5% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information on exacerbation before enrolment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe and very severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inclusion criteria ≤ 50% predicted</p> <p>Mean FEV<sub>1</sub>% predicted tiotropium + LABA/ICS group = 38.1% and tiotropium group = 37.7% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Required to have had ≥ 1 exacerbation in previous year</p> <p>Mean exacerbations last year: 1.4 for both groups, range 1‐7</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>COPD: chronic obstructive pulmonary disease</p> <p>FEV<sub>1</sub>: forced expiratory volume in one second </p> <p>LABA: long‐acting beta‐agonists</p> <p>ICS: inhaled corticosteroids</p> </div> </div> <p><a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> is a randomised, double‐blind, placebo‐controlled study that was conducted in Canada with the aim of comparing the safety and effectiveness of tiotropium plus placebo versus tiotropium plus fluticasone plus salmeterol as one‐year maintenance therapy in participants with moderate or severe COPD. This study included 449 participants (301 in a comparison of interest in this review) older than 35 years of age, with a forced expiratory volume in one second (FEV<sub>1</sub>)–to‐forced vital capacity (FVC) ratio of less than 0.70 and a post‐bronchodilator FEV<sub>1</sub> of less than 65% of the predicted value. Participants had to have at least one exacerbation of COPD that required treatment with systemic steroids or antibiotics within the 12 months before randomisation. Participants were assigned to receive tiotropium plus placebo or tiotropium plus fluticasone‐salmeterol. Measures of efficacy included the proportion of participants who experienced an exacerbation of COPD that required treatment with systemic steroids or antibiotics, lung function, disease‐specific quality of life, number of hospitalisations for COPD exacerbations and all‐cause hospitalisations. It is likely that most participants in this study would be eligible for triple therapy according to current guidance (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). </p> <p><a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a> is a randomised, double‐blind, double‐dummy, parallel‐group study that was conducted in Italy to compare the efficacy and safety of three treatments for 12 weeks: (1) fluticasone/salmeterol (FSC) 500/50 mg Diskus, one inhalation twice daily + placebo Handihaler, one inhalation once daily; (2) tiotropium 18 mg Handihaler, one inhalation once daily + placebo Diskus, one inhalation twice daily; (3) FSC 500/50 mg Diskus, one inhalation twice daily + tiotropium 18 mg Handihaler, one inhalation once daily. This study included 90 participants 50 years of age or older with well‐controlled severe or very severe COPD (FEV<sub>1</sub>% predicted ≤ 50%) who were current or former smokers (20 or more pack‐years) and were randomised to receive FSC, tiotropium or their combination. Study authors provided no information on the exacerbation status of participants during the year before enrolment. The primary efficacy measure was the mean change from baseline in pre‐dose FEV<sub>1</sub> after three‐months of treatment. Secondary efficacy measures included change from baseline in the validity assessment score (VAS) assessing dyspnoea and supplemental salbutamol. It is likely that most participants in this study would be eligible for triple therapy according to current guidance (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). </p> <p><a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a> is a randomised, double‐blind, parallel‐group, multi‐centre study of 24 weeks, conducted at 33 centres in the USA to compare the efficacy and safety of FSC (250/50 mcg twice daily) when added to tiotropium (18 mcg once daily) in participants with symptomatic moderate to severe COPD. The study included 342 participants who were 40 years of age or older with a cigarette smoking history ≥ 10 pack‐years and with a diagnosis of COPD and post‐bronchodilator FEV<sub>1</sub> ≥ 40% to ≤ 80% of predicted normal and FEV<sub>1</sub>/FVC of 0.70. In the year before enrolment, 43% of participants in the tiotropium plus FSC group had experienced at least one exacerbation, and 33% in the tiotropium alone group. Participants were randomised in a 1:1 double‐blind fashion to open‐label tiotropium 18 mcg once daily plus FSC 250/50 mcg twice daily or open‐label tiotropium 18 mcg once daily plus placebo twice daily. Measures of efficacy included evaluation of lung function (pre‐dose FEV<sub>1</sub>, post‐dose FEV<sub>1</sub>, pre‐dose FVC and post‐dose FVC), use of rescue medication, healthcare utilisation for COPD exacerbations, health status evaluated with domain scores on the Chronic Respiratory Disease Questionnaire‐Self Administered Standardised (CRQ‐SAS) and safety. It is likely that most participants in this study would not be recommended triple therapy according to current guidance (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). </p> <p><a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a> is a randomised, open‐label, parallel‐group study conducted in Japan with the aim of comparing the efficacy and tolerability of salmeterol/fluticasone propionate added to tiotropium for 12 weeks. This study included 30 participants with an FEV<sub>1</sub>/FVC ratio less than 0.70, a smoking history &gt; 10 pack‐years and no history of asthma or atopy. Eligible participants had mild to very severe COPD and were newly diagnosed or had not been treated previously with LAMA, LABA or ICS. Investigators provided no information on the exacerbation status of participants in the year before enrolment. They were randomised to receive inhaled tiotropium once daily or inhaled SFC twice daily, in combination with tiotropium once daily, for 12 weeks. Measures of efficacy included changes in airway dimensions on computed tomography (CT), pulmonary function testing and assessments of health‐related quality of life using the SGRQ. It is unclear what proportion of participants in this study would be eligible for triple therapy according to current guidance (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). </p> <p><a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> is a randomised, open‐label, multi‐centre two‐arm parallel‐group study conducted in 30 academic hospital‐based pulmonary clinics in Korea with the aim of comparing the efficacy of tiotropium (18 mg once daily) plus FSC (250/50 mg twice daily) versus tiotropium monotherapy. This study included 479 participants diagnosed with moderate to very severe COPD, who had a post‐bronchodilator FEV<sub>1</sub>/FVC ratio less than 0.70 and FEV<sub>1</sub> less than 65% of predicted value; eligible participants were 40 to 80 years of age and had a smoking history of at least 10 pack‐years. Investigators provided no information on the exacerbation status of participants in the year before enrolment. Participants were randomised to one of two treatment groups for 24‐week treatment: tiotropium 18 mg once daily; or tiotropium 18 mg once daily plus FSC, 250/50 mg/puff, one puff twice daily. Measures of efficacy included evaluation of lung function (change in pre‐bronchodilator FEV<sub>1</sub> (L); changes in pre‐bronchodilator inspiratory capacity (IC); FVC and percent predicted (% pred) values for FEV<sub>1</sub>); mean changes in health‐related quality of life; frequency of COPD exacerbations; exacerbations requiring hospitalisation, emergency room visits or outpatient clinic visits; and hospitalisation rates for all causes. It is unclear what proportion of participants in this study would be recommended triple therapy according to current guidance (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>), but likely it would be less than half. </p> <p><a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> is a randomised, double‐blind, parallel‐group, multi‐centre study conducted to compare the efficacy and tolerability of budesonide/formoterol added to tiotropium for 12 weeks. This study included 660 participants with severe or very severe COPD, with a pre‐bronchodilator FEV<sub>1</sub> not exceeding 50% of predicted normal value and a history of at least one exacerbation requiring systemic steroids and/or antibiotics in the previous year. Participants were randomised to receive tiotropium 18 mg once daily plus budesonide/formoterol 320/9 mg one inhalation twice daily or placebo twice daily. Measures of efficacy included clinic assessment of lung function and health status (change in pre‐dose FEV<sub>1</sub>, pre‐dose and post‐dose spirometry measurements and SGRQ for COPD), morning lung function assessments, COPD symptoms and morning activities, use of reliever medication, exacerbations and tolerability. It is likely that most of the participants in this study would be eligible for triple therapy according to current guidance (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). </p> </section> <section id="CD008532-sec-0068"> <h5 class="title">Economic evaluation analysis</h5> <p>Of the three economic analyses included, two (<a href="./references#CD008532-bbs2-0042" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] ">Mittmann 2011</a>; <a href="./references#CD008532-bbs2-0047" title="NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] ">Nielsen 2013</a>) reported on the economic evaluation conducted alongside the <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> clinical trial (the CLIMB trial) in six of the nine participant countries; <a href="./references#CD008532-bbs2-0047" title="NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] ">Nielsen 2013</a> conducted the economic evaluation in four Nordic countries (Sweden, Denmark, Finland, Norway) and <a href="./references#CD008532-bbs2-0042" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] ">Mittmann 2011</a> in three countries (Canada, Australia, Sweden); both study authors reported on the incremental cost‐effectiveness ratio for exacerbation avoided with tiotropium + LABA/ICS relative to tiotropium from the healthcare system perspective. <a href="./references#CD008532-bbs2-0043" title="NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. ">Najafzadeh 2008</a> conducted the economic evaluation from the Canadian healthcare system perspective alongside the <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> study (OPTIMAL trial) and reported on the incremental cost‐effectiveness ratio per exacerbation avoided and the incremental cost‐effectiveness ratio per quality‐adjusted life‐year (QALY). Investigators calculated the utilities used for the cost‐utility analysis from the results of SGRQ as applied to trial participants. </p> <p>We have presented detailed characteristics of these economic evaluations in <a href="#CD008532-tbl-0002">Table 1</a>. </p> </section> </section> <section id="CD008532-sec-0069"> <h4 class="title">Excluded studies</h4> <p>The initial search carried out in July 2010 revealed eight studies that failed to meet eligibility criteria for the review (see the <a href="./references#CD008532-sec-0134" title="">Characteristics of excluded studies</a> table). Four of these compared tiotropium alone with combination therapy (<a href="./references#CD008532-bbs2-0007" title="AndoF , RuggeriP , GirbinoG , CazzolaM . Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD. Respiratory Medicine2008;102(6):815‐8. ">Ando 2008</a>; <a href="./references#CD008532-bbs2-0008" title="BatemanE , Van‐DykM , ChangA . A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 851. BatemanED , VanDykM , SagriotisA . Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study. Pulmonary Pharmacology and Therapeutics2008; Vol. 21, issue 1:20‐5. ">Bateman 2008</a>; <a href="./references#CD008532-bbs2-0010" title="GolabiP , TopalogluN , KarakurtS , CelikelT . Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation dyspnea and exercise tolerance in COPD [Abstract]. European Respiratory Journal2006; Vol. 28, issue Suppl 50:33s [E304]. ">Golabi 2006</a>; <a href="./references#CD008532-bbs2-0011" title="HaraK , KurashimaK , TokunagaD , UenoM , AoyagiK , IsobeZ , et al. Single blind comparison of tiotropium and salmeterol plus fluticasone propionate of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A1. ">Hara 2007</a>), and one study compared tiotropium with LABA alone (<a href="./references#CD008532-bbs2-0014" title="PetroianniA , CeccarelliD , ContiV , GrazianiE , TerzanoC . Evening administration of tiotropium during combination therapy reduces night symptoms in COPD patients [Abstract]. European Respiratory Society 18th Annual Congress; 2008 Oct 3‐7; Berlin2008:[E4282]. ">Petroianni 2008</a>). The remaining three studies were shorter than three months in duration (<a href="./references#CD008532-bbs2-0009" title="BiscioneG , CrignaG , AucielloL , PasquaF , CazzolaM . Addition of tiotropium (T) to a regular treatment with long‐acting beta‐agonist + inhaled corticosteroid (LABA + ICS) in patients with severe to very‐severe COPD under in‐patient pulmonary rehabilitation program (PRP) [Abstract]. European Respiratory Society Annual Congress; 2009 Sep 12‐16; Vienna. 2009:[P526]. ">Biscione 2009</a>; <a href="./references#CD008532-bbs2-0013" title="PerngDW , WuCC , SuKC , LeeYC , PerngRP , TaoCW . Additive benefits of tiotropium in COPD patients treated with long‐acting beta2 agonists and corticosteroids. Respirology2006;11(5):598‐602. ">Perng 2006</a>), and one used a cross‐over design (<a href="./references#CD008532-bbs2-0016" title="SinghD , BrooksJ , HaganG , CahnA , O'ConnorBJ . Superiority of &quot;triple&quot; therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax2008;63(7):592‐8. SinghD , HaganG , CahnA , LeonardTB , RileyJH , O'ConnorBJ . Individual and combined responses to salmeterol/fluticasone propionate combination (SFC) and tiotropium (Tio) shown in a COPD clinical trial [Abstract]. American Thoracic Society International Conference; 2008 May 16‐21; Toronto. 2008:A648[#F10]. ">Singh 2008</a>). </p> <p>Searches updated to April 2015 identified seven studies that failed to meet eligibility criteria for the review (see the <a href="./references#CD008532-sec-0134" title="">Characteristics of excluded studies</a> table). Two of these evaluated tiotropium versus placebo (<a href="./references#CD008532-bbs2-0017" title="TashkinD . Impact of tiotropium on the course of moderate‐to‐very severe chronic obstructive pulmonary disease: the UPLIFT® trial. Expert Review of Respiratory Medicine2010;4(3):279–89. ">Tashkin 2008</a>; <a href="./references#CD008532-bbs2-0018" title="TroostersT , CelliB , KestenS . Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial. Primary Care Respiratory Journal2010;19(2):A13. ">Troosters 2008</a>), and one study compared tiotropium alone versus the LABA/ICS combination (<a href="./references#CD008532-bbs2-0015" title="SaracP . Comparison of the efficacy and safety of long‐acting anticholinergic and a combination of inhaled steroids and long‐acting beta‐2 agonist in moderate chronic obstructive pulmonary disease. European Respiratory Journal2013;42(Suppl 57):P4143. ">Sarac 2013</a>). One study (<a href="./references#CD008532-bbs2-0012" title="MaltaisF , MahlerD . Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD. European Respiratory Journal2013;42:539–41. [DOI: 10.1183/09031936.00074113] ">Maltais 2013</a>) was shorter than three months, and four were added to <a href="./references#CD008532-bbs1-0003" title="">Studies awaiting classification</a> and <a href="./references#CD008532-bbs1-0004" title="">Ongoing studies</a>. </p> </section> </section> <section id="CD008532-sec-0070"> <h3 class="title">Risk of bias in included studies</h3> <p>We have presented the assessment of risk of bias in the <a href="./references#CD008532-sec-0133" title="">Characteristics of included studies</a> table, and an overview of the findings in <a href="#CD008532-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD008532-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008532-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>We have summarised results of the quality assessment of economic evaluation studies in <a href="#CD008532-tbl-0003">Table 2</a>. We assessed all included economic evaluations according to their full‐text publications. In general, the economic evaluations included met the methodological and reporting aspects evaluated by the Drummond checklist, and their results can be considered valid (<a href="./references#CD008532-bbs2-0029" title="DrummondMF , JeffersonTO . Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ1996;313:275‐83. [DOI: 10.1136/bmj.313.7052.275] ">Drummond 1996</a>). In the economic evaluations conducted by <a href="./references#CD008532-bbs2-0042" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] ">Mittmann 2011</a>, <a href="./references#CD008532-bbs2-0047" title="NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] ">Nielsen 2013</a> and <a href="./references#CD008532-bbs2-0043" title="NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. ">Najafzadeh 2008</a>, discounting was not applied to costs and consequences. However, this was considered to be methodologically correct because the time horizon used in these analyses was three months and one year, respectively, making discounting unnecessary. </p> <section id="CD008532-sec-0071"> <h4 class="title">Allocation</h4> <p><a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>, <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> and <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> reported adequate sequence generation and allocation concealment. Details for <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> were supplied on request. For these three studies, randomisation was computer‐generated through central allocation, and both research staff and participants were blinded to the treatment assignment until the end of the study. For <a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>, <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a> and <a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a>, sequence generation and/or allocation concealment is unclear because study authors did not report full details and did not respond to personal communication. </p> </section> <section id="CD008532-sec-0072"> <h4 class="title">Blinding</h4> <p><a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>, <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a> and <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> performed a blinded outcome assessment. In the trial arms of <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>, inhalers containing placebo and fluticasone/salmeterol were identical in taste and appearance, and they were enclosed in identical tamper‐proof blinding devices. Medication canisters within the blinding devices were stripped of identifying labelling. Clinical data for suspected exacerbations were reviewed by a blinded committee to judge whether data met the study definition of COPD exacerbation. Blinding of participants was not broken for participants who prematurely discontinued treatment with study medications, and the statistician who performed the analysis was initially blinded to participant group assignments. In <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>, the DISKUS inhalers containing placebo and fluticasone‐salmeterol were identical in taste and appearance. In <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>, treatment assignment was concealed, as active and placebo inhalers were of identical appearance and both clinicians and participants were blinded to treatment until completion of the study. <a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a> was an open study; however, for evaluation of airway dimensions, a single observer, who was blind to all participant data, measured the outcome. <a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a> and <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> did not report details of the outcome assessment; therefore blinding is unclear for these studies. </p> </section> <section id="CD008532-sec-0073"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>, <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> and <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> reported comparable attrition rates (&lt; 14%) for both intervention and control groups; reasons for attrition were provided in all cases, making the risk of bias low. In <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>, withdrawal rates were different between intervention groups (74 participants (47%) withdrew from the tiotropium + placebo group, and 37 participants (26%) from the tiotropium + LABA/ICS group); however, mortality data were obtained for all participants, apart from six (2/145 on tiotropium + LABA/ICS and 4/156 on tiotropium + placebo) who withdrew and declined to be involved further in the study; therefore, we rated risk of bias as unclear. <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a> had high withdrawal rates in both groups (21% in fluticasone/salmeterol (FSC) + tiotropium group and 25% in tiotropium + placebo group); reasons for attrition were provided and were similar among groups; therefore, we rated this study as having an unclear risk of bias. In <a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a>, a total of 36 participants were enrolled in the study, but only 30 were included in the analysis (16 participants on FSC + tiotropium and 14 on tiotropium + placebo); therefore the withdrawal rate was 20% because of loss to follow‐up, making risk of attrition bias unclear. </p> </section> <section id="CD008532-sec-0074"> <h4 class="title">Selective reporting</h4> <p>All six studies adequately reported outcome data for primary and secondary outcomes that were pre‐specified in the study record. </p> </section> </section> <section id="CD008532-sec-0075"> <h3 class="title" id="CD008532-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD008532-tbl-0001"><b>Summary of findings for the main comparison</b> Tiotropium + LABA/ICS combination compared with tiotropium for chronic obstructive pulmonary disease</a> </p> <p>Because of the small number of eligible studies for the two comparisons (tiotropium + LABA/ICS vs tiotropium alone and vs LABA/ICS alone), no subgroup analysis by disease severity or by type of combination therapy was possible. </p> <section id="CD008532-sec-0076"> <h4 class="title">Comparison 1. Tiotropium plus LABA/ICS versus tiotropium</h4> <p>We identified six RCTs addressing the comparison of tiotropium + LABA/ICS versus tiotropium + placebo (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>; <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>; <a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a>; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>). </p> <section id="CD008532-sec-0077"> <h5 class="title">Primary outcomes</h5> <section id="CD008532-sec-0078"> <h6 class="title">All‐cause mortality</h6> <p>Two studies (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>) reported mortality at three months and 12 months of follow‐up, respectively. Both studies recruited participants who, on average, were likely to have fulfilled current GOLD criteria for triple therapy (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). These two studies did not find a significant effect on mortality with the use of tiotropium + LABA/ICS compared with tiotropium + placebo. Meta‐analysis of these studies showed a non‐statistically significant trend towards reduced risk of mortality with the use of tiotropium + LABA/ICS (two studies; 961 participants; OR 1.80, 95% CI 0.55 to 5.91; I<sup>2</sup> = 0%). The quality of evidence for this outcome is moderate because of imprecision in estimates of effect (<a href="./full#CD008532-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD008532-sec-0079"> <h6 class="title">Hospital admission (all causes)</h6> <p>The same two studies (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>) reported on all causes of hospital admission at three months and 12 months of follow‐up, respectively. <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> did not find a significant difference in hospital admissions at three months of follow‐up. <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> found a statistically significant reduction in hospital admission at 12 months of follow‐up with the use of tiotropium + LABA/ICS. Meta‐analysis of these studies (<a href="#CD008532-fig-0003">Figure 3</a>) showed a non statistically significant trend towards to decreased risk of hospital admission associated with the use of tiotropium + LABA/ICS (two studies; 961 participants; OR 0.84, 95% CI 0.53 to 1.33; I<sup>2</sup> = 0%); the quality of evidence for this outcome is low because of the risk of bias in included studies and imprecision of the estimate (<a href="./full#CD008532-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD008532-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.2 Hospital admission (all causes)." data-id="CD008532-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.2 Hospital admission (all causes). </p> </div> </div> </div> </section> <section id="CD008532-sec-0080"> <h6 class="title">Exacerbations</h6> <p>Three studies (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>) reported on exacerbations at three, six and 12 months of follow‐up, respectively. <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> found a significant difference in exacerbations at three months of follow‐up with the use of combined therapy tiotropium + LABA/ICS (one study; 660 participants; OR 0.36, 95% CI 0.22 to 0.60). <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> did not find a significant difference in exacerbations at six months of follow‐up (one study; 479 participants; OR 0.83, 95%CI 0.52 to 1.34). <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> did not find a statistically significant reduction in exacerbations at 12 months of follow‐up with the use of combined therapy tiotropium + LABA/ICS (one study; 301 participants; OR 0.89, 95% CI 0.56 to 1.41). We did not pool study results because statistical heterogeneity across studies was considerable. Of note, <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> may have recruited a population of participants with less severe COPD, not all of whom would be recommended triple therapy according to current guidelines. The quality of evidence for this outcome is low because of the risk of bias and imprecision in estimates of effect (<a href="./full#CD008532-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD008532-sec-0081"> <h6 class="title">Quality of life</h6> <p>Four studies (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a>; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>) reported on quality of life using the SGRQ (<a href="./references#CD008532-bbs2-0040" title="MeguroM , BarleyEA , SpencerS , JonesPW . Development and validation of an improved, COPD‐specific version of the St. George Respiratory Questionnaire. Chest2007; Vol. 132, issue 2:456‐63. ">Meguro 2007</a>) at six months. The meta‐analysis of these studies showed a statistically significant difference in quality of life (SGRQ total score) in favour of combined therapy of tiotropium + LABA/ICS compared with tiotropium + placebo (<a href="#CD008532-fig-0004">Figure 4</a>) (four studies; 1446 participants; MD ‐3.46, 95% CI ‐5.05 to ‐1.87; I<sup>2</sup> = 16%). Only one study reported on the percentage of participants who were responders to treatment. <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> reported the percentage of participants with improvement in SGRQ score greater than four units, which was significantly higher in the tiotropium + LABA/ICS group (49.5%) than in the tiotropium + placebo group (40.0%) (P value = 0.016). The percentage of participants who showed deterioration in SGRQ score greater than four units was similar in the two groups (tiotropium + LABA/ICS 27.6%, tiotropium + placebo 29.7%). </p> <div class="figure" id="CD008532-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.4 Quality of life up to 6 months (SGRQ)." data-id="CD008532-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.4 Quality of life up to 6 months (SGRQ). </p> </div> </div> </div> <p>The sensitivity analysis excluding two open‐label studies, which also included participants with less severe COPD (<a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a>; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>), revealed no changes in the direction of treatment effect (two studies; 961 participants; MD ‐2.5, 95% CI ‐4.16 to ‐0.84; I<sup>2</sup> = 0%). </p> <p>The quality of evidence for this outcome is low because of very serious risk of bias in the trial design (<a href="./full#CD008532-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD008532-sec-0082"> <h6 class="title">Exercise tolerance</h6> <p>None of the included studies reported exercise tolerance as an outcome.</p> </section> <section id="CD008532-sec-0083"> <h6 class="title">Serious adverse events non‐fatal (all reported)</h6> <p>Four studies (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>) reported on serious adverse events (non‐fatal). <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> reported no differences in serious adverse events between intervention groups; a total of 19 serious adverse events not related to COPD (respiratory failure, cancer and myocardial infarction or acute arrhythmia) were reported in both intervention groups, and one case of pneumonia in the combined therapy group. <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> reported no differences in serious adverse event rates between trial arms; the event most commonly reported in the combined therapy group was productive cough, whereas dyspnoea was the most common event in the tiotropium group. Two cases of pneumonia were reported in each intervention group. <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a> reported no statistically significant differences in serious adverse event rates between therapy groups; two cases of pneumonia were reported in the combined therapy group, and nobody in the tiotropium presented with pneumonia. In <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>, six cases of pneumonia were reported in each trial arm as serious adverse events, representing &lt; 1% of the total adverse events reported by the trial. </p> <p>Meta‐analysis for all non‐fatal serious adverse events reported in these studies showed no statistically significant differences (four studies; 1758 participants; OR 0.86, 95% CI 0.57 to 1.30; I<sup>2</sup> = 9%) (<a href="#CD008532-fig-0005">Figure 5</a>). The sensitivity analysis excluding the open‐label study (<a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>) revealed no differences in the treatment effect estimation (three studies; 1303 participants; OR 0.67, 95% CI 0.4 to 1.13; I<sup>2</sup> = 0%). Exclusion of both <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a> and <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> from the meta‐analysis on the basis of the less severe population recruited widened the CIs but had little impact on size and direction of the effect. </p> <div class="figure" id="CD008532-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.7 Serious adverse events all reported (non‐fatal)." data-id="CD008532-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.7 Serious adverse events all reported (non‐fatal). </p> </div> </div> </div> <p>The quality of evidence for this outcome is low because of risk of bias and imprecision in estimates of effect (<a href="./full#CD008532-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Independent meta‐analysis for pneumonia including four studies (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>) revealed no statistically significant differences in effects on pneumonia between treatments (four studies; 1758 participants; Peto OR 1.62, 95% CI 0.54 to 4.82; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD008532-sec-0084"> <h5 class="title">Secondary outcomes</h5> <section id="CD008532-sec-0085"> <h6 class="title">Symptoms</h6> <p><a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> was the only included study that reported changes in COPD symptom scores for breathlessness (MD ‐0.142, 95% CI ‐0.214 to ‐0.069), night awakening (MD ‐0.157, 95% CI ‐0.222 to ‐0.092), chest tightness (MD ‐0.142, 95% CI ‐0.212 to ‐0.072) and cough (MD ‐0.161, 95% CI ‐0.238 to ‐0.084) among 660 participants. Scores for all symptoms favoured the tiotropium + LABA/ICS group compared with the tiotropium + placebo group. </p> </section> <section id="CD008532-sec-0086"> <h6 class="title">Forced expiratory volume in one second (FEV<sub>1</sub>) </h6> <p>Six studies (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>; <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>; <a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a>; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>) reported mean change in FEV<sub>1</sub> at three to six months. These studies found statistically significant changes in FEV<sub>1</sub> with the use of tiotropium + LABA/ICS compared with tiotropium + placebo (four studies; 1678 participants; MD 0.06, 95% CI 0.04 to 0.08; I<sup>2</sup> = 0%; <a href="#CD008532-fig-0006">Figure 6</a>); however, these changes are not clinically significant. The quality of evidence for this outcome is moderate as a result of the risk of bias. </p> <div class="figure" id="CD008532-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.4 FEV1 pre‐dose." data-id="CD008532-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.4 FEV<sub>1</sub> pre‐dose. </p> </div> </div> </div> <p><a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a> was excluded from the analysis because all data were not available. <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a> was not included in the pooled estimates of effect because this study generated significant heterogeneity (I<sup>2</sup> &gt; 90%). We considered the statistical heterogeneity to result from differences in baseline risk, as participants in <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a> had on average a greater degree of dyspnoea (modified Medical Research Council scale (MRCm) &gt; 2), which may have resulted in a greater response to pharmacological management. </p> <p>Exclusion of <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> due to concerns about the relevance of the recruited population to current guidelines on triple therapy had a minimal impact on size and direction of the effect estimate (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). </p> </section> <section id="CD008532-sec-0087"> <h6 class="title">Adverse events (not serious)</h6> <p>Four studies (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>; <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>) reported adverse events. These studies did not find statistically significant differences with the use of tiotropium + LABA/ICS compared to tiotropium + placebo. Meta‐analysis of these studies did not show a statistically significant difference (four studies; 1363 participants OR 1.16, 95% CI 0.92 to 1.47, I<sup>2</sup> = 0%). Removing <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>, a study in which the participants may not, on average, have fulfilled current GOLD criteria for receiving triple therapy, had little impact on the outcome (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). </p> </section> <section id="CD008532-sec-0088"> <h6 class="title">Cost‐effectiveness of interventions</h6> <p>In the economic evaluation conducted by <a href="./references#CD008532-bbs2-0042" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] ">Mittmann 2011</a>; <a href="./references#CD008532-bbs2-0047" title="NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] ">Nielsen 2013</a> Tiotropium+ LABA/ICS was the dominant strategy (less costly and more effective) in three of the countries where it was assessed, in comparison with Tiotropium (Canada, Australia and Norway) (<a href="#CD008532-tbl-0002">Table 1</a>). In all other countries including Sweden, Finland, Denmark and Norway the ICER per exacerbation avoided was under the established willingness to pay threshold (between 600 to 1000 EUR); therefore the Tiotropium + LABA/ICS therapy resulted in a cost‐effective alternative. Sensitivity analyses in both studies indicated that the variables with the largest effect on the ICER were hospitalisation costs, the incidence of exacerbations and hospital admission‐related costs. </p> <p>In the study conducted by <a href="./references#CD008532-bbs2-0043" title="NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. ">Najafzadeh 2008</a> Tiotropium + LABA/ICS showed significantly better quality of life and less hospital admissions than Tiotropium alone, but this improvement in health outcomes was associated with increased costs. The Tiotropium therapy showed the highest probability of being cost‐effective when the "willingness to pay" is CAN $6.000°°; when QALY was used as the effectiveness outcome, treatment with Tiotropium had the highest probability of being the best option compared to Tiotropium + LABA/ICS. </p> </section> </section> </section> <section id="CD008532-sec-0089"> <h4 class="title">Comparison 2. Tiotropium plus LABA/ICS versus LABA/ICS</h4> <p><a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a> was the only eligible study identified that compared tiotropium + LABA/ICS versus LABA/ICS + placebo (60 participants) and recruited those with severe or very severe COPD at baseline, most of whom were likely to have met current GOLD criteria for triple therapy (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). This study reported results for the following outcomes of interest for this review. </p> <section id="CD008532-sec-0090"> <h5 class="title">Primary outcome</h5> <section id="CD008532-sec-0091"> <h6 class="title">Mortality (all‐cause)</h6> <p><a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a> reported zero serious adverse events; therefore, we assumed that no deaths occurred during the study. </p> </section> </section> <section id="CD008532-sec-0092"> <h5 class="title">Secondary outcomes</h5> <section id="CD008532-sec-0093"> <h6 class="title">Forced expiratory volume in one second (FEV<sub>1</sub>) </h6> <p>Tiotropium in combination with LABA/ICS improves FEV<sub>1</sub> significantly compared with LABA/ICS + placebo (MD 0.05, 95% CI 0.00 to 0.09), but MD and CI were below the minimally clinically important difference of 100 to 140 mL. </p> </section> <section id="CD008532-sec-0094"> <h6 class="title">Serious adverse events (non‐fatal)</h6> <p>No serious adverse events were reported in either intervention group.</p> </section> <section id="CD008532-sec-0095"> <h6 class="title">Adverse events</h6> <p>More adverse events were reported in the tiotropium + LABA/ICS group (15/30) than in the tiotropium + placebo group (8/30), but the CI was wide because of the small numbers of participants (OR 2.75, 95% CI 0.93 to 8.10). </p> </section> <section id="CD008532-sec-0096"> <h6 class="title">Withdrawal</h6> <p>Fewer withdrawals were reported in the tiotropium + LABA/ICS group (1/30) than in the tiotropium + placebo group (4/30), but the number of events was small and was not statistically significant (OR 0.22, 95% CI 0.02 to 2.14). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008532-sec-0097" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008532-sec-0097"></div> <section id="CD008532-sec-0098"> <h3 class="title" id="CD008532-sec-0098">Summary of main results</h3> <p>This systematic review set out to investigate the long‐term (≥ three months) effects of tiotropium in combination with long‐acting beta‐agonists/inhaled corticosteroids (LABA/ICS) compared with either LABA/ICS alone or tiotropium alone for the treatment of chronic obstructive pulmonary disease (COPD). We identified six randomised controlled trials (RCTs). All six studies looked at the effects of combination therapy (tiotropium + LABA/ICS) compared with tiotropium alone, whereas only one of these studies (<a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>) compared triple therapy versus LABA/ICS alone. Additionally, we included three cost‐effectiveness analyses based on data from two of these studies (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>) for evaluation of economic outcomes. </p> <section id="CD008532-sec-0099"> <h4 class="title">Tiotropium + LABA/ICS versus tiotropium</h4> <p>Since the first version of this systematic review was published, three clinical trials comparing tiotropium + LABA/ICS versus tiotropium alone have been published (<a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>; <a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a>; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>). These three trials reported on quality of life; exacerbations, FEV<sub>1</sub> and non serious adverse events but do not report on hospital admission and mortality; therefore the evidence for the last two outcomes remain the same that failed to show a statistically significant difference in mortality and hospital admission between tiotropium + LABA/ICS versus tiotropium alone (moderate and low quality of evidence). Participants recruited to the two studies included in the analyses of hospitalisations and mortality (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>) are likely to have been candidates for tiotropium + LABA/ICS therapy according to current guidance <a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a> (i.e. forced expiratory volume in one second (FEV<sub>1</sub>) &lt; 50% predicted and frequent exacerbations ), suggesting that these findings are clinically applicable. </p> <p>Even though investigators found statistically significant differences between treatment arms for other important outcomes such as FEV<sub>1</sub> and quality of life, these results must be interpreted with caution, as the differences found may not be clinically significant. According to <a href="./references#CD008532-bbs2-0036" title="JonesPW . St. George’s Respiratory Questionnaire: MCID. COPD2005;2:75‐9. ">Jones 2005</a>, the minimal clinically important difference (MCID) for FEV<sub>1</sub> may vary but is accepted to be within the range of 100 to 140 mL (American Thoracic Society/European Respiratory Society Task Force). In this review, the difference in treatment effect on FEV<sub>1</sub> was 60 mL; this difference did not reach the MCID needed to have a beneficial impact on participants' quality of life (<a href="./references#CD008532-bbs2-0036" title="JonesPW . St. George’s Respiratory Questionnaire: MCID. COPD2005;2:75‐9. ">Jones 2005</a>). Similarly, the MCID in quality of life scores evaluated with St. George's Respiratory Questionnaire (SGRQ) has been proposed to be four units of improvement; the meta‐analysis for this outcome showed a difference smaller than a four‐unit change that could be reached just as part of a Hawthorne effect. Westwood et al described that in participants with COPD, a Hawthorne effect influences SGRQ scores in COPD trials; typically, this results in improvement of two to three points on the SGRQ with placebo (<a href="./references#CD008532-bbs2-0052" title="WestwoodM , BourbeauJ , JonesPW , CerulliA , Capkun‐NiggliG , WorthyG . Relationship between FEV1 change and patient‐reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respiratory Research2011;12:40. ">Westwood 2011</a>). <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> reported a percentage of participants with improvement in SGRQ score greater than four units, which was significantly higher in the tiotropium + LABA/ICS group (49.5%) than in the tiotropium + placebo group (40.0%) (P value = 0.016). The percentage of participants with a decrease in SGRQ score greater than four units was similar in the two groups (tiotropium + LABA/ICS 27.6%, tiotropium + placebo 29.7%). </p> <p>Of note, <a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a> and <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> contributed data to the quality of life analysis, and <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> to the FEV<sub>1</sub> analysis, but on average, participants included in these studies may not have been candidates for tiotropium + LABA/ICS therapy according to current guidelines (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). However, removing these studies from the analyses had little impact on the size or direction of the effect estimate. </p> <p>We did not pool data on exacerbations reported in these studies, as we considered that several sources of variation among the studies resulted in important heterogeneity (I<sup>2</sup> &gt; 80%) that could not be removed by subgroup analyses based on length of follow‐up (three, six and 12 months) (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>; <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a>) nor by the definition of exacerbation used (<a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> defined exacerbation as worsening of COPD leading to treatment with systemic steroids and/or antibiotics; <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> cited the definition of Rodriguez‐Roisin: sustained worsening of the patient's condition from the stable state and beyond normal day‐to‐day variations that is acute in onset and necessitates a regular change in medication in a patient with underlying COPD; and <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> defined an exacerbation as worsening of COPD leading to treatment with systemic steroids and/or hospitalisation/emergency room visits). All these individual studies failed to show significant differences in exacerbations between the two treatment arms at six and 12 months of follow‐up. The study by <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> showed a significant reduction in the risk of exacerbation at three‐month follow‐up associated with triple therapy in comparison with tiotropium alone. However, this finding may be considered clinically irrelevant because the follow‐up period needed to define the real effect that any COPD treatment could have on exacerbation is 52 months (<a href="./references#CD008532-bbs2-0027" title="CazzolaM , MacNeeW , MartinezFJ , RabeKF , FranciosiLG , BarnesPJ , et al. American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal2008;31(2):416–69. [DOI: 10.1183/09031936.00099306] ">Cazzola 2008</a>; <a href="./references#CD008532-bbs2-0041" title="MiravitllesM , FerrerM , PontA , ZalacainR , Alvarez‐SalaJL , MasaF . Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax2004;59(5):387–95. ">Miravitlles 2004</a>). </p> <p>The effect of tiotropium + LABA/ICS combination treatment on mortality remains uncertain because of the small number of events. The difference in serious adverse event rates between intervention groups was not statistically significant. For pneumonia, the number of cases in each study was small compared with the number of withdrawals and the number of participants lost to follow‐up. Withdrawals did not seem to be linked to adverse events but rather to the efficacy of treatment. Even though use of inhaled corticosteroids has been associated with pneumonia, our findings suggest no safety concerns related to use of the tiotropium + LABA/ICS combination in the treatment of patients with COPD when compared with tiotropium alone. </p> <p>Economic evaluation results show a high probability that tiotropium + LABA/ICS combination treatment could be a cost‐effective alternative in various settings, as it was associated with fewer hospital admissions and better quality of life, which may drive most of the long‐term costs associated with this condition. The two economic evaluations conducted in Canada (<a href="./references#CD008532-bbs2-0042" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] ">Mittmann 2011</a>; <a href="./references#CD008532-bbs2-0043" title="NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. ">Najafzadeh 2008</a>) differ in the final conclusions presented regarding cost‐effectiveness of combined therapy (tiotropium + LABA/ICS); these differences may be explained by differences in willingness to pay thresholds used in the sensitivity analyses, making comparison of the conclusions of these two studies impossible. </p> </section> <section id="CD008532-sec-0100"> <h4 class="title">LABA/ICS + tiotropium versus LABA/ICS + placebo</h4> <p>The one pilot study (<a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>; no publications after 2007) that looked at the effect of LABA/ICS + tiotropium versus LABA/ICS + placebo showed significantly greater improvement in FEV<sub>1</sub> with tiotropium + LABA/ICS compared with LABA/ICS; however, the mean difference in FEV<sub>1</sub> was not clinically significant. All other outcomes of interest were not studied, revealed no events or did not achieve a statistically significant difference. </p> </section> </section> <section id="CD008532-sec-0101"> <h3 class="title" id="CD008532-sec-0101">Overall completeness and applicability of evidence</h3> <p>For the comparison of benefits and risks of treatment with tiotropium + LABA/ICS versus LABA/ICS, we identified just one small eligible study (<a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>), which did not look at, or report on, any of the primary outcomes specified in this review, except for mortality. Therefore, this review found little applicable evidence for this comparison. </p> <p>Current international guidance suggests that triple therapy with long‐acting muscarinic agonists (LAMA), LABA and ICS should be reserved for patients who continue to have symptoms despite receiving dual therapy with either LABA/ICS or LABA + LAMA, have an FEV<sub>1</sub> &lt; 50% predicted and are at a high risk of experiencing exacerbations (i.e. ≥ two exacerbations in the preceding year) (<a href="./references#CD008532-bbs2-0031" title="From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org/ (accessed 11 June 2015). ">GOLD 2015</a>). Lack of detailed reporting of baseline characteristics has somewhat limited our ability to assess to what extent the studies included in this review recruited participants who would meet these criteria. This could potentially limit the generalisability of our findings to a clinical setting. <a href="#CD008532-tbl-0004">Table 3</a> summarises the available information, and, when relevant, we performed a sensitivity analysis that excluded the study or studies in which investigators raised concerns about the relevance of the recruited population. This did not have a substantial impact on any of the effect estimates. We have also included in the individual analyses footnotes that detail the baseline characteristics of participants included in the analysis. </p> </section> <section id="CD008532-sec-0102"> <h3 class="title" id="CD008532-sec-0102">Quality of the evidence</h3> <p>Methods used for randomisation and outcome assessment in some of the included studies were not clearly described and in some cases explanations were missing, thus presenting a source of potential bias. </p> <p>The quality of the evidence, according to the GRADE (Grades of Recommendation, Assessment, Development and Evaluation Working Group) framework, was moderate for mortality but low for hospital admissions and other important outcomes such as exacerbations, adverse events and quality of life (<a href="./references#CD008532-bbs2-0032" title="SchünemannH , BrożekJ , GuyattG , OxmanA . Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. http://www.guidelinedevelopment.org/handbook/#h.buaodtl66dyx (accessed 11 June 2015). ">GRADE 2013</a>). </p> </section> <section id="CD008532-sec-0103"> <h3 class="title" id="CD008532-sec-0103">Potential biases in the review process</h3> <p>The issue of large and/or uneven numbers of withdrawals, as mentioned above (<a href="#CD008532-sec-0102">Quality of the evidence</a>), will, even if addressed, have a high likelihood of introducing selection bias, as no consensus has been reached on how best to handle participants for whom no data are available. The high drop‐off rates observed in these types of studies may have been a consequence of the long‐term follow‐up required to measure effectiveness outcomes. </p> <p>We analysed available data as specified in the protocol. However, we expanded the review question from the protocol to include the comparison of tiotropium + LABA/ICS versus LABA/ICS + placebo. We also highlighted the percentage of participants with a clinically significant change in health‐related quality of life as reported by study authors, although this was not specified in <a href="#CD008532-sec-0055">Measures of treatment effect</a>. </p> </section> <section id="CD008532-sec-0104"> <h3 class="title" id="CD008532-sec-0104">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD008532-bbs2-0039" title="LiuY , ShiH , SunX . Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta‐analysis. European Journal of Internal Medicine2014;25(5):491‐5. [DOI: 10.1016/j.ejim.2014.04.007] ">Liu 2014</a> and <a href="./references#CD008532-bbs2-0049" title="RodrigoGJ , PlazaV , Castro‐RodríguezJA . Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulmonary Pharmacology &amp; Therapeutics2012;25(1):40‐7. [DOI: 10.1016/j.pupt.2011.10.006] ">Rodrigo 2012</a> published reviews that evaluated the long‐term efficacy and adverse effects of tiotropium + LABA/ICS treatment compared with tiotropium. Both reviews revealed benefits for lung function, quality of life and exacerbation risk. Our review validates these findings. However, with respect to this last outcome, we believe it is not advisable to combine the results, given that length of follow‐up differed among the studies, that the only study that showed length of follow‐up to 52 weeks is <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> and that results should be presented independently, as has been done in the present review. The present review also describes a beneficial impact on hospitalisation risk, another clinically relevant outcome that was not previously considered. Additionally, the current review presents results reflecting the GRADE method, which allows the reader to consider the quality of the evidence for each outcome ‐ a critical piece of information on which to base clinical decisions. </p> <p>A systematic review looking at LABA/ICS combination treatment compared with placebo has shown that combination treatment significantly reduces mortality and exacerbation rates and improves lung function (<a href="./references#CD008532-bbs2-0046" title="NanniniLJ , PooleP , MilanSJ , HolmesR , NormansellR . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD003794.pub4] ">Nannini 2013</a>). LABA/ICS also increases the risk of pneumonia compared with placebo. A systematic review comparing tiotropium versus placebo showed that tiotropium treatment was associated with a significant improvement in participants' quality of life and reduced the risk of exacerbations, with a number needed to treat for an additional beneficial outcome (NNTB) of 16 to prevent one exacerbation. Tiotropium also reduced exacerbations leading to hospitalisation when compared with placebo (<a href="./references#CD008532-bbs2-0037" title="KarnerC , ChongJ , PooleP . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD009285.pub3] ">Karner 2014</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008532-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008532-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008532-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.2 Hospital admission (all causes)." data-id="CD008532-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.2 Hospital admission (all causes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.4 Quality of life up to 6 months (SGRQ)." data-id="CD008532-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.4 Quality of life up to 6 months (SGRQ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.7 Serious adverse events all reported (non‐fatal)." data-id="CD008532-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.7 Serious adverse events all reported (non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.4 FEV1 pre‐dose." data-id="CD008532-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, outcome: 1.4 FEV<sub>1</sub> pre‐dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 1 Mortality (all‐cause)." data-id="CD008532-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 1 Mortality (all‐cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 2 Hospital admission (all causes)." data-id="CD008532-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 2 Hospital admission (all causes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 3 Exacerbation." data-id="CD008532-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 3 Exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 4 Quality of life up to 6 months (SGRQ)." data-id="CD008532-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 4 Quality of life up to 6 months (SGRQ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 5 Sensitivity analysis ‐ QoL up to 6 months (SGRQ)." data-id="CD008532-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 5 Sensitivity analysis ‐ QoL up to 6 months (SGRQ). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 6 FEV1 pre‐dose." data-id="CD008532-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 6 FEV<sub>1</sub> pre‐dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-CMP-001-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 7 Serious adverse events all reported (non‐fatal)." data-id="CD008532-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 7 Serious adverse events all reported (non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 8 Pneumonia." data-id="CD008532-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 8 Pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 9 Sensitivity analysis ‐ SAE all reported (non‐fatal)." data-id="CD008532-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 9 Sensitivity analysis ‐ SAE all reported (non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 10 Adverse event." data-id="CD008532-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Tiotropium + LABA/ICS combination versus tiotropium + placebo, Outcome 10 Adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tiotropium + LABA/ICS combination vs LABA/ICS combination + placebo, Outcome 1 FEV1 GIV." data-id="CD008532-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Tiotropium + LABA/ICS combination vs LABA/ICS combination + placebo, Outcome 1 FEV<sub>1</sub> GIV. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tiotropium + LABA/ICS combination vs LABA/ICS combination + placebo, Outcome 2 Adverse event." data-id="CD008532-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Tiotropium + LABA/ICS combination vs LABA/ICS combination + placebo, Outcome 2 Adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008532-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/urn:x-wiley:14651858:media:CD008532:CD008532-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_t/tCD008532-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Tiotropium + LABA/ICS combination vs LABA/ICS combination + placebo, Outcome 3 FEV1." data-id="CD008532-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Tiotropium + LABA/ICS combination vs LABA/ICS combination + placebo, Outcome 3 FEV<sub>1</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/media/CDSR/CD008532/image_n/nCD008532-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008532-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tiotropium + LABA/ICS combination compared with tiotropium for chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Tiotropium + LABA/ICS combination compared with tiotropium for chronic obstructive pulmonary disease </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with chronic obstructive pulmonary disease </p> <p><b>Settings:</b> ambulatory clinics </p> <p><b>Intervention</b>:tiotropium + LABA/ICS combination </p> <p><b>Comparison:</b> tiotropium </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> <p><b>Tiotropium</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> <p><b>Tiotropium + LABA/ICS combination</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality (all‐cause)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (5 to 47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.80<br/> (0.55 to 5.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>961<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital admission (all causes)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/> (69 to 145) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.84<br/> (0.53 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>961<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝ ⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbation ‐ at 12‐month follow‐up</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>628 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>601 per 1000<br/> (486 to 704) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.89<br/> (0.56 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events (non‐fatal)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000<br/> (35 to 76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.86<br/> (0.57 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1758<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <sup>a,c</sup> <br/> Low </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life up to 6 months (SGRQ)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ up to 6 months in the intervention groups was 3.46 lower (5.05 to 1.87 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(4 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝ <sup>d</sup> <br/> Low </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A lower score indicates better quality of life</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> pre‐dose ‐ FEV<sub>1</sub> 3‐6 months mean difference </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean FEV<sub>1</sub> pre‐dose ‐ FEV<sub>1</sub> 3‐6 months mean difference in the intervention groups was 0.06 (0.04 to 0.08 ) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(4 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> pre‐dose ‐ FEV<sub>1</sub> 1 year </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean FEV<sub>1</sub> pre‐dose ‐ FEV<sub>1</sub> 1 year mean difference in the intervention groups was 0.06 (0 to 0.12 ) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>OR</b>: odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level because of imprecision (95% confidence interval includes both no effect and appreciable harm) </p> <p><sup>b</sup>Downgraded one level because of study limitations (incomplete outcome assessment in <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>) </p> <p><sup>c</sup>Downgraded once because of study limitations (incomplete outcome assessment in <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> and <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>; unclear risk of selection bias in <a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a>; possible detection bias in <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>) </p> <p><sup>d</sup>Downgraded two levels because of study limitations (unclear risk of selection bias and detection bias and incomplete outcome assessment in <a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a>; unclear risk of detection bias in <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>; incomplete outcome assessment in <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>) </p> <p><sup>e</sup>Downgraded one level because of study limitations (unclear risk of selection and detection bias in <a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a>; unclear risk of detection bias in <a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a>; incomplete outcome assessment in <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Tiotropium + LABA/ICS combination compared with tiotropium for chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008532-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included economic evaluations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Population</b> </p> <p><b> (N participants, severity indicators, smoking history</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Economic outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Intervention<sup>a</sup> (doses)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Perspective</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Price year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Time horizon</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> ICER reported and adjusted to Euros 2014</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0043" title="NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. ">Najafzadeh 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cost utility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Based on the <a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> study: </p> <p>N = 449, patients with ≥ 1 exacerbation within 12 months, moderate and severe obstruction defined as FEV<sub>1</sub> &lt; 65% post‐bronchodilator, ≥ 10 pack‐years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incremental cost per exacerbation avoided and incremental cost per QALY with tiotropium + LABA/ICS relative to tiotropium </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>• Tiotropium 18 mcg once daily + placebo twice daily</p> <p>• Tiotropium 18 mcg once daily + FS 250/25 mg/puff, 2 puffs twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Healthcare</p> <p>system perspective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per exacerbation avoid CAN$6510</p> <p>Per QALY CAN$243180</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0042" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] ">Mittmann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Australia, Canada and Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Based on the <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> study: </p> <p>N = 659, aged ≥ 40 years, symptoms for ≥ 2 years, ≥ 1 exacerbation within 12 months requiring systemic steroids and/or antibiotics, FEV<sub>1</sub> ≤ 50% of predicted normal, FEV<sub>1</sub> /FVC &lt; 70% pre‐dose, ≥ 10 pack‐years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incremental cost‐effectiveness ratio for exacerbation avoided with tiotropium + LABA/ICS relative to tiotropium </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>• Tiotropium (Handihaler) 18 mcg once daily + budesonide/formoterol (Symbicort Turbuhaler) 320/9 mcg one inhalation twice daily </p> <p>• Tiotropium 18 mcg once daily + placebo (identical Turbuhaler) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Healthcare system payer perspective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per avoiding severe exacerbation: Australia: tiotropium + LABA/ICS dominant</p> <p>Canadian:</p> <p>tiotropium + LABA/ICS dominant</p> <p>Sweden:</p> <p>244,36 EUR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0047" title="NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] ">Nielsen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denmark, Finland, Norway and Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Based on the <a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> study: </p> <p>N = 659, aged ≥ 40 years, clinical diagnosis of COPD and symptoms ≥ 2 years, ≥ 1 exacerbation in the previous 12 months requiring systemic steroids and/or antibiotics, FEV<sub>1</sub> ≤ 50% predicted normal value, FEV<sub>1</sub> /FVC &lt; 70% pre‐dose, ≥10 pack‐years </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Incremental cost‐effectiveness ratio for exacerbation avoided with tiotropium + LABA/ICS relative to tiotropium </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>• Tiotropium (Handihaler) 18 mcg once daily + budesonide/formoterol (Symbicort Turbuhaler) 320/9 mcg one inhalation twice daily </p> <p>• Tiotropium 18 mcg once daily + placebo (identical Turbuhaler) twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Healthcare system payer perspective</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ICER excluding antibiotics Denmark:</p> <p>212 EUR</p> <p>Finland:</p> <p>307 EUR</p> <p>Norway:</p> <p>tiotropium + LABA/ICS dominant</p> <p>Sweden:</p> <p>165 EUR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>Tiotropium was compared with tiotropium + budesonide/formoterol in all included economic evaluations. </p> <p>CEA: cost‐effectiveness analysis</p> <p>FEV<sub>1</sub>: forced expiratory volume in one second </p> <p>FVC: forced vital capacity</p> <p>ICER: incremental cost‐effectiveness ratio</p> <p>ICS: inhaled corticosteroids</p> <p>LABA: long‐acting beta‐agonists</p> <p>QALY: quality‐adjusted life‐year</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included economic evaluations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008532-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Quality assessment of included economic evaluations (Drummond checklist)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Well‐defined question?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Competing alternatives described?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Effectiveness established?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Relevant costs and consequences identified?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Costs and consequences measured accurately?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Costs and consequences valued credibly?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Discounting performed?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Incremental analysis of costs and consequences performed?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Sensitivity analysis performed?</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0042" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] ">Mittmann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0043" title="NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. ">Najafzadeh 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0047" title="NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] ">Nielsen 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Quality assessment of included economic evaluations (Drummond checklist)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008532-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included studies: baseline COPD severity and exacerbation status</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline COPD severity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline FEV<sub>1</sub>% predicted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Exacerbation status preceding enrolment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0001" title="AaronSD , VandemheenK , FergusonD , FitzGeraldM , MaltaisF , BoureauJ , et al. The Canadian optimal therapy of COPD trial: design, organization and patient recruitment. Canadian Respiratory Journal2004;11(8):581‐5. AaronSD , VandemheenKL , FergussonD , MaltaisF , BourbeauJ , GoldsteinR , et al. Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2007;146(8):545‐55. KaplanA . Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal2007;16(4):258‐60. NajafzadehM , MarraCA , SadatsafaviM , AaronSD , SullivanSD , VandemheenKL , et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax2008;63(11):962‐7. RoismanG . Tiotropium in combination with placebo, salmeterol, or fluticasone‐salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique2007;63(6):390‐1. ">Aaron 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate or severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inclusion criteria &lt; 65% predicted</p> <p>Mean FEV<sub>1</sub>% predicted tiotropium + LABA/ICS group 42.2% and in tiotropium group 42.1% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Required to have had ≥ 1 exacerbation in previous year</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0002" title="CazzolaM , AndoF , SantusP , RuggeriP , DiMarcoF , SanduzziA , et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe‐to‐very severe COPD. Pulmonary Pharmacology and Therapeutics2007;20(5):556‐61. D'AmatoM , AndoF , SantusP , RuggeriP , DiMarcoF , CazzolaM . Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe‐to‐very severe COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):218. ">Cazzola 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe and very severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inclusion criteria ≤ 50% predicted</p> <p>Mean FEV<sub>1</sub>% predicted LABA/ICS group = 36.9%, tiotropium group = 38.5%, tiotropium + LABA/ICS group = 39% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information on exacerbation status before enrolment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0003" title="HananiaNA , CraterGD , MorrisAN , EmmettAH , O'DellDM , NiewoehnerDE . Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respiratory Medicine2012;106(1):91‐101. [PUBMED: PMID: 22040533.] ">Hanania 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate: tiotropium + LABA/ICS = 63% and tiotropium = 72%</p> <p>Severe: tiotropium + LABA/ICS = 37% and tiotropium = 28%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inclusion criteria ≥ 40 to ≤ 80% predicted</p> <p>Mean FEV<sub>1</sub>% predicted tiotropium + LABA/ICS group = 56% and tiotropium group = 57.4% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Exacerbations in past 12 months requiring antibiotics/corticosteroid: tiotropium + LABA/ICS: 1 exacerbation = 37%, ≥ 2 exacerbations = 6% </p> <p>Tiotropium: 1 exacerbation = 27%, ≥ 2 exacerbations = 6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0004" title="HoshinoM , OhtawaJ . Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease. Respirology2011;16(1):95–101. [DOI: 10.1111/j.1440‐1843.2010.01869.x] ">Hoshino 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to very severe</p> <p>Overall: mild = 10%, moderate = 33%, severe = 36.6%, very severe = 20%.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean FEV<sub>1</sub>% predicted tiotropium + LABA/ICS group = 64.6% and tiotropium group = 57.1% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants were excluded if they had experienced an exacerbation in the previous 12 weeks before commencement of the study. No other information on exacerbation status </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0005" title="JungKS , ParkHY , ParkSY , KimSK , KimYK , ShimJJ , et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respiratory Medicine2012;106(3):382‐9. [MEDLINE: doi: 10.1016] ">Jung 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate: tiotropium + LABA/ICS = 56.6% and tiotropium = 60.3%</p> <p>Severe: tiotropium + LABA/ICS = 40.8% and tiotropium = 35.5%</p> <p>Very severe: tiotropium + LABA/ICS = 2.7% and tiotropium = 3.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inclusion criteria &lt; 65% predicted</p> <p>Mean FEV<sub>1</sub>% predicted tiotropium + LABA/ICS group = 47.4% and tiotropium group = 47.5% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information on exacerbation before enrolment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008532-bbs2-0006" title="MittmannN , HernandezP . Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish Healthcare Perspectives. Pharmacoeconomics2011;29(5):403‐14. [PUBMED: 21504240] NielsenR , KankaanrantaH , BjermerL . Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine2013;107(11):1709‐21. [DOI: http://dx.doi.org/10.1016/j.rmed.2013.06.007] WelteT , HartmanL , PolanowskiT , HernandezP . Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20 San Diego. 2009:A6188 [Poster #215]. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest2009;136(4):26S‐f. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest2009;136(4):24S‐g. WelteT , MiravitllesM , HernandezP , ErikssonG , PetersonS , PolanowskiT , et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2009;180(8):741‐50. WelteT , MiravitllesM , HernandezP , HartmanL , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms &amp; morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress; Sep 12‐16; Vienna. 2009:[P2005]. WelteT , MiravitllesM , HernandezP , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation‐related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress; September 12‐16; Vienna. 2009:[P2012]. WelteT , MiravitllesM , PetersonS , PolanowskiT , KesslerR . Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6192 [Poster #216]. ">Welte 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe and very severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inclusion criteria ≤ 50% predicted</p> <p>Mean FEV<sub>1</sub>% predicted tiotropium + LABA/ICS group = 38.1% and tiotropium group = 37.7% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Required to have had ≥ 1 exacerbation in previous year</p> <p>Mean exacerbations last year: 1.4 for both groups, range 1‐7</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>COPD: chronic obstructive pulmonary disease</p> <p>FEV<sub>1</sub>: forced expiratory volume in one second </p> <p>LABA: long‐acting beta‐agonists</p> <p>ICS: inhaled corticosteroids</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included studies: baseline COPD severity and exacerbation status</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/full#CD008532-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008532-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tiotropium + LABA/ICS combination versus tiotropium + placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality (all‐cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.55, 5.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 3‐month follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [0.12, 74.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 12‐month follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.45, 5.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospital admission (all causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.53, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 3‐month follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.27, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 12‐month follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.55, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 3‐month follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At 6‐month follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 At 12‐month follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life up to 6 months (SGRQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.33 [‐4.72, ‐1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Sensitivity analysis ‐ QoL up to 6 months (SGRQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐4.16, ‐0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 FEV<sub>1</sub> pre‐dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 FEV1 3‐6 months mean difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.04, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 FEV1 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serious adverse events all reported (non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.57, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.54, 4.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Sensitivity analysis ‐ SAE all reported (non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.40, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.92, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Tiotropium + LABA/ICS combination versus tiotropium + placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008532-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tiotropium + LABA/ICS combination vs LABA/ICS combination + placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 FEV<sub>1</sub> GIV <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Tiotropium + LABA/ICS combination vs LABA/ICS combination + placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008532.pub3/references#CD008532-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008532.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008532-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008532-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008532-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008532-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008532-note-0012">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008532\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008532\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008532\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008532\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008532\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008532.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008532.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008532.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008532.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008532.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715780085"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008532.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715780089"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008532.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8f6e59aef55f',t:'MTc0MDcxNTc4MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 